JP2016513717A - 置換キサンチンおよびその使用方法 - Google Patents
置換キサンチンおよびその使用方法 Download PDFInfo
- Publication number
- JP2016513717A JP2016513717A JP2016502662A JP2016502662A JP2016513717A JP 2016513717 A JP2016513717 A JP 2016513717A JP 2016502662 A JP2016502662 A JP 2016502662A JP 2016502662 A JP2016502662 A JP 2016502662A JP 2016513717 A JP2016513717 A JP 2016513717A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- methyl
- dione
- purine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 88
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title description 3
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 279
- 150000001875 compounds Chemical class 0.000 claims abstract description 221
- 102000003621 TRPC5 Human genes 0.000 claims abstract description 95
- 101150042815 TRPC5 gene Proteins 0.000 claims abstract description 95
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims description 150
- 125000003118 aryl group Chemical group 0.000 claims description 69
- 150000003839 salts Chemical class 0.000 claims description 56
- 125000001072 heteroaryl group Chemical group 0.000 claims description 52
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 41
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 38
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 37
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 36
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- 125000004104 aryloxy group Chemical group 0.000 claims description 33
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 33
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 30
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 27
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 27
- 230000001404 mediated effect Effects 0.000 claims description 27
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 229940100389 Sulfonylurea Drugs 0.000 claims description 19
- 125000002252 acyl group Chemical group 0.000 claims description 19
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 19
- 235000013877 carbamide Nutrition 0.000 claims description 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 150000001408 amides Chemical class 0.000 claims description 17
- 239000004202 carbamide Substances 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 17
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 15
- 125000005864 sulfonamidyl group Chemical group 0.000 claims description 15
- 125000003368 amide group Chemical group 0.000 claims description 13
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000000335 thiazolyl group Chemical group 0.000 claims description 12
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 150000003672 ureas Chemical class 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 abstract description 21
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 495
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 335
- 239000000243 solution Substances 0.000 description 167
- 230000014759 maintenance of location Effects 0.000 description 155
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 153
- 239000000543 intermediate Substances 0.000 description 146
- 239000007787 solid Substances 0.000 description 146
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 126
- 238000006243 chemical reaction Methods 0.000 description 124
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 123
- 239000012044 organic layer Substances 0.000 description 116
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 107
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 93
- 229910052938 sodium sulfate Inorganic materials 0.000 description 93
- 235000011152 sodium sulphate Nutrition 0.000 description 93
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 86
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 85
- 239000012043 crude product Substances 0.000 description 79
- 239000003921 oil Substances 0.000 description 79
- 235000019198 oils Nutrition 0.000 description 79
- 239000012267 brine Substances 0.000 description 77
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 77
- 238000005160 1H NMR spectroscopy Methods 0.000 description 61
- 235000019441 ethanol Nutrition 0.000 description 55
- 239000003208 petroleum Substances 0.000 description 51
- 208000002193 Pain Diseases 0.000 description 46
- 229910000027 potassium carbonate Inorganic materials 0.000 description 43
- 230000036407 pain Effects 0.000 description 42
- 238000010898 silica gel chromatography Methods 0.000 description 39
- 239000011575 calcium Substances 0.000 description 36
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
- 238000000746 purification Methods 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 230000000694 effects Effects 0.000 description 30
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- 239000010410 layer Substances 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 108090000862 Ion Channels Proteins 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 239000012065 filter cake Substances 0.000 description 17
- 229920006395 saturated elastomer Polymers 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 238000002953 preparative HPLC Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 235000019270 ammonium chloride Nutrition 0.000 description 14
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 14
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 12
- 230000004907 flux Effects 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- 239000012279 sodium borohydride Substances 0.000 description 11
- 229910000033 sodium borohydride Inorganic materials 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000006188 syrup Substances 0.000 description 10
- 235000020357 syrup Nutrition 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 206010010904 Convulsion Diseases 0.000 description 8
- 208000001640 Fibromyalgia Diseases 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000000825 ultraviolet detection Methods 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- HJNHUFQGDJLQRS-UHFFFAOYSA-N 2-(3-bromopropoxy)oxane Chemical compound BrCCCOC1CCCCO1 HJNHUFQGDJLQRS-UHFFFAOYSA-N 0.000 description 6
- BAYTZPDBXASXLK-UHFFFAOYSA-N 2-chloro-5-hydroxybenzaldehyde Chemical compound OC1=CC=C(Cl)C(C=O)=C1 BAYTZPDBXASXLK-UHFFFAOYSA-N 0.000 description 6
- UWLJERQTLRORJN-UHFFFAOYSA-N 3-(trifluoromethoxy)phenol Chemical compound OC1=CC=CC(OC(F)(F)F)=C1 UWLJERQTLRORJN-UHFFFAOYSA-N 0.000 description 6
- NNTKLJOVVSAISR-UHFFFAOYSA-N 6-amino-5-[(4-chlorophenyl)methylamino]-3-methyl-1h-pyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)NC(N)=C1NCC1=CC=C(Cl)C=C1 NNTKLJOVVSAISR-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 206010031009 Oral pain Diseases 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000004781 alginic acids Chemical class 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 5
- FQBDLEGJZOWRBK-UHFFFAOYSA-N 2-amino-7-benzyl-3h-purin-6-one Chemical compound C1=NC=2NC(N)=NC(=O)C=2N1CC1=CC=CC=C1 FQBDLEGJZOWRBK-UHFFFAOYSA-N 0.000 description 5
- ZFWMXPWCTPNAGZ-UHFFFAOYSA-N 3-methyl-8-[3-(trifluoromethoxy)phenoxy]-7-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C[Si](C)(C)CCOCN1C=2C(=O)NC(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 ZFWMXPWCTPNAGZ-UHFFFAOYSA-N 0.000 description 5
- UJAFGNAOINNEKQ-UHFFFAOYSA-N 4-chloro-3-hydroxybenzaldehyde Chemical compound OC1=CC(C=O)=CC=C1Cl UJAFGNAOINNEKQ-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- UXXLJIWQNXOESK-UHFFFAOYSA-N 8-bromo-3-methyl-7-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound O=C1NC(=O)N(C)C2=C1N(COCC[Si](C)(C)C)C(Br)=N2 UXXLJIWQNXOESK-UHFFFAOYSA-N 0.000 description 5
- 239000004342 Benzoyl peroxide Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940122657 TRPC5 antagonist Drugs 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000019400 benzoyl peroxide Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000007913 intrathecal administration Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 5
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 229960002900 methylcellulose Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- JNHDLNXNYPLBMJ-UHFFFAOYSA-N 1,3-thiazol-2-ylmethanol Chemical compound OCC1=NC=CS1 JNHDLNXNYPLBMJ-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- BXCZTQRACVHZIB-UHFFFAOYSA-N 2-(chloromethyl)-5-methyl-1,3-thiazole Chemical compound CC1=CN=C(CCl)S1 BXCZTQRACVHZIB-UHFFFAOYSA-N 0.000 description 4
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 4
- HELSCPRKLIJMBU-UHFFFAOYSA-N 3-hydroxybutyl 4-methylbenzenesulfonate Chemical compound CC(O)CCOS(=O)(=O)C1=CC=C(C)C=C1 HELSCPRKLIJMBU-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ONZJZLLLWSNKKJ-UHFFFAOYSA-N 4-chloro-3-(morpholin-4-ylmethyl)phenol Chemical compound OC1=CC=C(Cl)C(CN2CCOCC2)=C1 ONZJZLLLWSNKKJ-UHFFFAOYSA-N 0.000 description 4
- FRGLXUVLFJOTPD-UHFFFAOYSA-N 5,6-diamino-3-[(4-methoxyphenyl)methyl]-1-methylpyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C)C(N)=C(N)C1=O FRGLXUVLFJOTPD-UHFFFAOYSA-N 0.000 description 4
- PTWYMEGORSLQQI-UHFFFAOYSA-N 7-benzyl-8-chloro-1-[3-(oxan-2-yloxy)propyl]-3-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C1=2C(=O)N(CCCOC3OCCCC3)C(=O)N(COCC[Si](C)(C)C)C=2N=C(Cl)N1CC1=CC=CC=C1 PTWYMEGORSLQQI-UHFFFAOYSA-N 0.000 description 4
- MVLUODCNIFDGDR-UHFFFAOYSA-N 7-benzyl-8-chloro-3-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C1=2C(=O)NC(=O)N(COCC[Si](C)(C)C)C=2N=C(Cl)N1CC1=CC=CC=C1 MVLUODCNIFDGDR-UHFFFAOYSA-N 0.000 description 4
- QTEQVEJOXGBDGI-UHFFFAOYSA-N 8-bromo-3-methyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(C)C2=C1NC(Br)=N2 QTEQVEJOXGBDGI-UHFFFAOYSA-N 0.000 description 4
- DFJNPLNFFLLZCH-UHFFFAOYSA-N 8-bromo-7-[(4-chlorophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C1=2C(=O)NC(=O)N(C)C=2N=C(Br)N1CC1=CC=C(Cl)C=C1 DFJNPLNFFLLZCH-UHFFFAOYSA-N 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 108091005462 Cation channels Proteins 0.000 description 4
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000010291 membrane polarization Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
- ZFRLRBGRGHNVPE-UHFFFAOYSA-N (2-hydroxycyclopentyl)methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1CCCC1O ZFRLRBGRGHNVPE-UHFFFAOYSA-N 0.000 description 3
- HOBMGFDJYBEWLS-UHFFFAOYSA-N (2-methylpyrimidin-5-yl)methanol Chemical compound CC1=NC=C(CO)C=N1 HOBMGFDJYBEWLS-UHFFFAOYSA-N 0.000 description 3
- CQMPPPAHJBQCOY-UHFFFAOYSA-N (4-methyl-1,3-thiazol-2-yl)methanol Chemical compound CC1=CSC(CO)=N1 CQMPPPAHJBQCOY-UHFFFAOYSA-N 0.000 description 3
- GGGJYJXAFSEWNM-UHFFFAOYSA-N (5-fluoropyridin-3-yl)methanol Chemical compound OCC1=CN=CC(F)=C1 GGGJYJXAFSEWNM-UHFFFAOYSA-N 0.000 description 3
- MDYHWQQHEWDJKR-UHFFFAOYSA-N (5-methyl-1,2-oxazol-3-yl)methanol Chemical compound CC1=CC(CO)=NO1 MDYHWQQHEWDJKR-UHFFFAOYSA-N 0.000 description 3
- JDRBDIIAXYFTIK-UHFFFAOYSA-N (5-methyl-1,3-oxazol-2-yl)methanol Chemical compound CC1=CN=C(CO)O1 JDRBDIIAXYFTIK-UHFFFAOYSA-N 0.000 description 3
- GZGPRZYZKBQPBQ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decane Chemical compound O1CCOC11CCCCC1 GZGPRZYZKBQPBQ-UHFFFAOYSA-N 0.000 description 3
- DAQCEOKMNCDVOV-UHFFFAOYSA-N 1-(2-aminoethyl)-7-[(4-chlorophenyl)methyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCN)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 DAQCEOKMNCDVOV-UHFFFAOYSA-N 0.000 description 3
- QVKGADWQMRNIPZ-UHFFFAOYSA-N 1-(2-bromoethyl)-7-[(4-chlorophenyl)methyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCBr)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 QVKGADWQMRNIPZ-UHFFFAOYSA-N 0.000 description 3
- BROSMYXVSSCLGP-UHFFFAOYSA-N 1-(2-bromoethyl)cyclopropan-1-ol Chemical compound BrCCC1(O)CC1 BROSMYXVSSCLGP-UHFFFAOYSA-N 0.000 description 3
- QGMKCAZXZBYWCH-UHFFFAOYSA-N 1-(2-hydroxyethyl)cyclopentan-1-ol Chemical compound OCCC1(O)CCCC1 QGMKCAZXZBYWCH-UHFFFAOYSA-N 0.000 description 3
- KMUSTGDHVRFWIJ-UHFFFAOYSA-N 1-(3-hydroxypropyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 KMUSTGDHVRFWIJ-UHFFFAOYSA-N 0.000 description 3
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 3
- ZJWNZZRPKUNTGN-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-3-methyl-8-[3-[3-(trifluoromethoxy)phenoxy]propyl]-7h-purine-2,6-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(NC(CCCOC=2C=C(OC(F)(F)F)C=CC=2)=N2)=C2N(C)C1=O ZJWNZZRPKUNTGN-UHFFFAOYSA-N 0.000 description 3
- JTTNSRLRJILAJP-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-3-methyl-8-[[3-(trifluoromethoxy)phenyl]methyl]-7h-purine-2,6-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(NC(CC=2C=C(OC(F)(F)F)C=CC=2)=N2)=C2N(C)C1=O JTTNSRLRJILAJP-UHFFFAOYSA-N 0.000 description 3
- UABLWSBEEPVEQM-UHFFFAOYSA-N 1-[2-(2-hydroxyethoxy)ethyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCOCCO)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 UABLWSBEEPVEQM-UHFFFAOYSA-N 0.000 description 3
- AQJAMJORJVLCHJ-UHFFFAOYSA-N 2-(2-ethyl-1,3-dioxolan-2-yl)ethanol Chemical compound OCCC1(CC)OCCO1 AQJAMJORJVLCHJ-UHFFFAOYSA-N 0.000 description 3
- IMGPENXHLMRWPT-UHFFFAOYSA-N 2-(2-ethyl-1,3-dioxolan-2-yl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1(CC)OCCO1 IMGPENXHLMRWPT-UHFFFAOYSA-N 0.000 description 3
- WTXQFNXZFWLAEQ-UHFFFAOYSA-N 2-(3-methoxyphenyl)-4-methyl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC=C(C)N=2)=C1 WTXQFNXZFWLAEQ-UHFFFAOYSA-N 0.000 description 3
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 3
- ZHAKAIBZKYHXJS-UHFFFAOYSA-N 2-(chloromethyl)-1,3-thiazole Chemical compound ClCC1=NC=CS1 ZHAKAIBZKYHXJS-UHFFFAOYSA-N 0.000 description 3
- IWIQIVZFDMPNNR-UHFFFAOYSA-N 2-(chloromethyl)-4-methyl-1,3-thiazole Chemical compound CC1=CSC(CCl)=N1 IWIQIVZFDMPNNR-UHFFFAOYSA-N 0.000 description 3
- OXXWQLSFICBOMG-UHFFFAOYSA-N 2-(chloromethyl)-5-methylpyridin-1-ium;chloride Chemical compound Cl.CC1=CC=C(CCl)N=C1 OXXWQLSFICBOMG-UHFFFAOYSA-N 0.000 description 3
- NGWOJHYZCOVKRC-UHFFFAOYSA-N 2-[3-(4-methyl-1,3-oxazol-2-yl)phenyl]acetic acid Chemical compound CC1=COC(C=2C=C(CC(O)=O)C=CC=2)=N1 NGWOJHYZCOVKRC-UHFFFAOYSA-N 0.000 description 3
- JHMKQDMFYHWCKP-UHFFFAOYSA-N 2-[3-(trifluoromethoxy)phenoxy]ethanol Chemical compound OCCOC1=CC=CC(OC(F)(F)F)=C1 JHMKQDMFYHWCKP-UHFFFAOYSA-N 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- LKXPDOQKELOUCP-UHFFFAOYSA-N 3,3,3-trifluoropropyl methanesulfonate Chemical compound CS(=O)(=O)OCCC(F)(F)F LKXPDOQKELOUCP-UHFFFAOYSA-N 0.000 description 3
- SVJYJYOEVSSJTJ-UHFFFAOYSA-N 3-(4-methyl-1,3-oxazol-2-yl)phenol Chemical compound CC1=COC(C=2C=C(O)C=CC=2)=N1 SVJYJYOEVSSJTJ-UHFFFAOYSA-N 0.000 description 3
- LQFKEKMQGLGYJC-UHFFFAOYSA-N 3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound CC1=CN=C(CCC(O)=O)S1 LQFKEKMQGLGYJC-UHFFFAOYSA-N 0.000 description 3
- FMCCVRHTUFNEPV-UHFFFAOYSA-N 3-(chloromethyl)-5-fluoropyridine Chemical compound FC1=CN=CC(CCl)=C1 FMCCVRHTUFNEPV-UHFFFAOYSA-N 0.000 description 3
- FEXTXBAFBURKGS-UHFFFAOYSA-N 3-(chloromethyl)-5-methyl-1,2-oxazole Chemical compound CC1=CC(CCl)=NO1 FEXTXBAFBURKGS-UHFFFAOYSA-N 0.000 description 3
- HUEZHIFQOMJURO-UHFFFAOYSA-N 3-[3-(trifluoromethoxy)phenoxy]propanoic acid Chemical compound OC(=O)CCOC1=CC=CC(OC(F)(F)F)=C1 HUEZHIFQOMJURO-UHFFFAOYSA-N 0.000 description 3
- ZUSASUZRNVBFOZ-UHFFFAOYSA-N 3-[3-(trifluoromethoxy)phenyl]prop-2-yn-1-ol Chemical compound OCC#CC1=CC=CC(OC(F)(F)F)=C1 ZUSASUZRNVBFOZ-UHFFFAOYSA-N 0.000 description 3
- FUBCIAHXKPFUCB-UHFFFAOYSA-N 3-[3-(trifluoromethoxy)phenyl]propan-1-ol Chemical compound OCCCC1=CC=CC(OC(F)(F)F)=C1 FUBCIAHXKPFUCB-UHFFFAOYSA-N 0.000 description 3
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 3
- ZDHGYRWBGAZWRM-UHFFFAOYSA-N 3-ethyl-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1NC(=O)N(CC)C2=C1N(CC=C)C=N2 ZDHGYRWBGAZWRM-UHFFFAOYSA-N 0.000 description 3
- QCORPNBKUPVMKS-UHFFFAOYSA-N 3-methyl-1-[3-(oxan-2-yloxy)propyl]-8-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCCOC3OCCCC3)C(=O)N(C)C=2N=C1OCCOC1=CC=CC(OC(F)(F)F)=C1 QCORPNBKUPVMKS-UHFFFAOYSA-N 0.000 description 3
- BZDZTWZGDYUFES-UHFFFAOYSA-N 3-methyl-7-[(5-methylpyridin-2-yl)methyl]-8-[[3-(trifluoromethoxy)phenyl]methyl]purine-2,6-dione Chemical compound N1=CC(C)=CC=C1CN1C(C(=O)NC(=O)N2C)=C2N=C1CC1=CC=CC(OC(F)(F)F)=C1 BZDZTWZGDYUFES-UHFFFAOYSA-N 0.000 description 3
- YRYTVWGEVDNVGE-UHFFFAOYSA-N 3-methyl-8-[3-(trifluoromethoxy)phenoxy]-1-(3,3,3-trifluoropropyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC(F)(F)F)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 YRYTVWGEVDNVGE-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- KNGVGMVHBVVSCF-UHFFFAOYSA-N 5,6-diamino-3-methyl-1h-pyrimidine-2,4-dione Chemical compound CN1C(=O)NC(N)=C(N)C1=O KNGVGMVHBVVSCF-UHFFFAOYSA-N 0.000 description 3
- OGCMYKGUHKUPCM-UHFFFAOYSA-N 5-(chloromethyl)-1,2-oxazole Chemical compound ClCC1=CC=NO1 OGCMYKGUHKUPCM-UHFFFAOYSA-N 0.000 description 3
- VOZUTBFGYYYZPY-UHFFFAOYSA-N 6-amino-3-[(4-methoxyphenyl)methyl]-1-methylpyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C)C(N)=CC1=O VOZUTBFGYYYZPY-UHFFFAOYSA-N 0.000 description 3
- GUDXLMQIDACJSU-UHFFFAOYSA-N 6-amino-3-methyl-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound CN1C(=O)NC(N)=C(N=O)C1=O GUDXLMQIDACJSU-UHFFFAOYSA-N 0.000 description 3
- HKZYVGRBPOSLPO-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(3-hydroxy-2-methoxypropyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(CO)OC)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 HKZYVGRBPOSLPO-UHFFFAOYSA-N 0.000 description 3
- JVIWCWAYAPAJJJ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-[2-(dimethylamino)ethyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione;hydrochloride Chemical compound Cl.C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCN(C)C)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 JVIWCWAYAPAJJJ-UHFFFAOYSA-N 0.000 description 3
- MSQBTCQIWQWBQV-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-[2-(dimethylamino)ethyl]-1-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(C)C(=O)N(CCN(C)C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 MSQBTCQIWQWBQV-UHFFFAOYSA-N 0.000 description 3
- AABHJGOBXPZAAF-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-1-(3-oxopentyl)-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCC(=O)CC)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 AABHJGOBXPZAAF-UHFFFAOYSA-N 0.000 description 3
- XXQXHVMRJMBRNG-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 XXQXHVMRJMBRNG-UHFFFAOYSA-N 0.000 description 3
- BMOHIFNMILGREZ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-8-[3-(trifluoromethyl)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1OC1=CC=CC(C(F)(F)F)=C1 BMOHIFNMILGREZ-UHFFFAOYSA-N 0.000 description 3
- AFCLEMNPGSUBDT-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-8-sulfanylidene-9h-purine-2,6-dione Chemical compound C1=2C(=O)NC(=O)N(C)C=2NC(=S)N1CC1=CC=C(Cl)C=C1 AFCLEMNPGSUBDT-UHFFFAOYSA-N 0.000 description 3
- CYLWXXZMKKRKLT-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[4-chloro-3-(trifluoromethyl)phenoxy]-1-[2-(2-hydroxyethoxy)ethyl]-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCOCCO)C(=O)N(C)C=2N=C1OC1=CC=C(Cl)C(C(F)(F)F)=C1 CYLWXXZMKKRKLT-UHFFFAOYSA-N 0.000 description 3
- BIFFUUURMCWVBB-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1CC1=CC(OC(F)(F)F)=CC=C1F BIFFUUURMCWVBB-UHFFFAOYSA-N 0.000 description 3
- SLIQAKVCZYWIJX-UHFFFAOYSA-N 7-benzyl-3-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C1=2C(=O)NC(=O)N(COCC[Si](C)(C)C)C=2N=CN1CC1=CC=CC=C1 SLIQAKVCZYWIJX-UHFFFAOYSA-N 0.000 description 3
- XRQASRNNGZWNMM-UHFFFAOYSA-N 7-benzyl-3-ethyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)NC(=O)N(CC)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 XRQASRNNGZWNMM-UHFFFAOYSA-N 0.000 description 3
- CYCIVUQZGSKPDJ-UHFFFAOYSA-N 7-benzyl-8-chloro-1-(3-hydroxypropyl)-3h-purine-2,6-dione Chemical compound C1=2C(=O)N(CCCO)C(=O)NC=2N=C(Cl)N1CC1=CC=CC=C1 CYCIVUQZGSKPDJ-UHFFFAOYSA-N 0.000 description 3
- JIJJUKPQSRDDIS-UHFFFAOYSA-N 7-benzyl-8-chloro-3-ethyl-1-(3-hydroxypropyl)purine-2,6-dione Chemical compound C1=2C(=O)N(CCCO)C(=O)N(CC)C=2N=C(Cl)N1CC1=CC=CC=C1 JIJJUKPQSRDDIS-UHFFFAOYSA-N 0.000 description 3
- CCNKGFXFVYFQPF-UHFFFAOYSA-N 7-prop-2-enyl-3h-purine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=CN2CC=C CCNKGFXFVYFQPF-UHFFFAOYSA-N 0.000 description 3
- JEKYSFJSNSYWHG-UHFFFAOYSA-N 8-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]-1-[(4-methoxyphenyl)methyl]-3-methyl-7h-purine-2,6-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(NC(CC=2C(=CC=C(OC(F)(F)F)C=2)F)=N2)=C2N(C)C1=O JEKYSFJSNSYWHG-UHFFFAOYSA-N 0.000 description 3
- SZQBFGUATCGUSS-UHFFFAOYSA-N 8-bromo-1-(3-hydroxybutyl)-3-methyl-7-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound O=C1N(CCC(O)C)C(=O)N(C)C2=C1N(COCC[Si](C)(C)C)C(Br)=N2 SZQBFGUATCGUSS-UHFFFAOYSA-N 0.000 description 3
- NNCKJSDKYWXRND-UHFFFAOYSA-N 8-bromo-1-(3-hydroxypropyl)-3-methyl-7-[(5-methyl-1,3-thiazol-2-yl)methyl]purine-2,6-dione Chemical compound S1C(C)=CN=C1CN1C(C(=O)N(CCCO)C(=O)N2C)=C2N=C1Br NNCKJSDKYWXRND-UHFFFAOYSA-N 0.000 description 3
- IXTOZZLGLQKMPB-UHFFFAOYSA-N 8-bromo-1-(3-hydroxypropyl)-3-methyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCO)C(=O)N(C)C2=C1NC(Br)=N2 IXTOZZLGLQKMPB-UHFFFAOYSA-N 0.000 description 3
- TWGSWHWTFLTGGS-UHFFFAOYSA-N 8-bromo-7-[(4-chlorophenyl)methyl]-3-methyl-1-[3-(oxan-2-yloxy)propyl]purine-2,6-dione Chemical compound C1=2C(=O)N(CCCOC3OCCCC3)C(=O)N(C)C=2N=C(Br)N1CC1=CC=C(Cl)C=C1 TWGSWHWTFLTGGS-UHFFFAOYSA-N 0.000 description 3
- BNQIJPRDJMTBJA-UHFFFAOYSA-N 8-bromo-7-[(4-fluorophenyl)methyl]-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C1=2C(=O)N(CCCO)C(=O)N(C)C=2N=C(Br)N1CC1=CC=C(F)C=C1 BNQIJPRDJMTBJA-UHFFFAOYSA-N 0.000 description 3
- PGHXZABUIDWURJ-UHFFFAOYSA-N 8-bromo-7-[(4-fluorophenyl)methyl]-3-methyl-1-[3-(oxan-2-yloxy)propyl]purine-2,6-dione Chemical compound C1=2C(=O)N(CCCOC3OCCCC3)C(=O)N(C)C=2N=C(Br)N1CC1=CC=C(F)C=C1 PGHXZABUIDWURJ-UHFFFAOYSA-N 0.000 description 3
- SALBMFUCETWNNL-UHFFFAOYSA-N 8-chloro-3-ethyl-1-(3-hydroxypropyl)-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1N(CCCO)C(=O)N(CC)C2=C1N(CC=C)C(Cl)=N2 SALBMFUCETWNNL-UHFFFAOYSA-N 0.000 description 3
- GNDGTRLLOKTNCQ-UHFFFAOYSA-N 8-chloro-3-ethyl-1-(3-hydroxypropyl)-7h-purine-2,6-dione Chemical compound O=C1N(CCCO)C(=O)N(CC)C2=C1NC(Cl)=N2 GNDGTRLLOKTNCQ-UHFFFAOYSA-N 0.000 description 3
- MLZZDSKRLJXNCK-UHFFFAOYSA-N 8-chloro-3-ethyl-7-prop-2-enylpurine-2,6-dione Chemical compound O=C1NC(=O)N(CC)C2=C1N(CC=C)C(Cl)=N2 MLZZDSKRLJXNCK-UHFFFAOYSA-N 0.000 description 3
- BJUGDYMLGOTUNK-UHFFFAOYSA-N 8-chloro-7-[(4-chlorophenyl)methyl]-1-(3-hydroxypropyl)-3h-purine-2,6-dione Chemical compound C1=2C(=O)N(CCCO)C(=O)NC=2N=C(Cl)N1CC1=CC=C(Cl)C=C1 BJUGDYMLGOTUNK-UHFFFAOYSA-N 0.000 description 3
- SLEFKSLQUXIJAU-UHFFFAOYSA-N 8-chloro-7-[(4-chlorophenyl)methyl]-1-methyl-3h-purine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)NC=2N=C(Cl)N1CC1=CC=C(Cl)C=C1 SLEFKSLQUXIJAU-UHFFFAOYSA-N 0.000 description 3
- AZTDFEVFCCYJKT-UHFFFAOYSA-N 8-chloro-7-[(4-chlorophenyl)methyl]-3-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C1=2C(=O)NC(=O)N(COCC[Si](C)(C)C)C=2N=C(Cl)N1CC1=CC=C(Cl)C=C1 AZTDFEVFCCYJKT-UHFFFAOYSA-N 0.000 description 3
- GLUBPSKWTLFUAC-UHFFFAOYSA-N 8-chloro-7-[(4-chlorophenyl)methyl]-3-ethyl-1-(3-hydroxypropyl)purine-2,6-dione Chemical compound C1=2C(=O)N(CCCO)C(=O)N(CC)C=2N=C(Cl)N1CC1=CC=C(Cl)C=C1 GLUBPSKWTLFUAC-UHFFFAOYSA-N 0.000 description 3
- UGCGFILDQNLNMW-UHFFFAOYSA-N 8-chloro-7-[(4-chlorophenyl)methyl]-3h-purine-2,6-dione Chemical compound ClC1=NC=2NC(=O)NC(=O)C=2N1CC1=CC=C(Cl)C=C1 UGCGFILDQNLNMW-UHFFFAOYSA-N 0.000 description 3
- KULSNSGMLQHLCV-UHFFFAOYSA-N 8-ethoxy-3-ethyl-1-(3-hydroxypropyl)-7h-purine-2,6-dione Chemical compound CCN1C(=O)N(CCCO)C(=O)C2=C1N=C(OCC)N2 KULSNSGMLQHLCV-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
- 238000011785 NMRI mouse Methods 0.000 description 3
- 101100426589 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) trp-3 gene Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 102000003629 TRPC3 Human genes 0.000 description 3
- 102000003623 TRPC6 Human genes 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 3
- 101150037542 Trpc3 gene Proteins 0.000 description 3
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 3
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- GIYHGLTYCWBNDV-SNAWJCMRSA-N ethyl (e)-3-(5-methyl-1,3-thiazol-2-yl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=NC=C(C)S1 GIYHGLTYCWBNDV-SNAWJCMRSA-N 0.000 description 3
- QLQYUDCEZVYBBQ-UHFFFAOYSA-N ethyl 3-(5-methyl-1,3-thiazol-2-yl)propanoate Chemical compound CCOC(=O)CCC1=NC=C(C)S1 QLQYUDCEZVYBBQ-UHFFFAOYSA-N 0.000 description 3
- QMMQCTJEKVXNDB-UHFFFAOYSA-N ethyl 3-[3-(trifluoromethoxy)phenoxy]propanoate Chemical compound CCOC(=O)CCOC1=CC=CC(OC(F)(F)F)=C1 QMMQCTJEKVXNDB-UHFFFAOYSA-N 0.000 description 3
- AVQLWUGRGBPYLN-UHFFFAOYSA-N ethyl 5-methyl-1,3-oxazole-2-carboxylate Chemical compound CCOC(=O)C1=NC=C(C)O1 AVQLWUGRGBPYLN-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- VDRQCADWGSAXPV-UHFFFAOYSA-N methyl 2-(2-ethyl-1,3-dioxolan-2-yl)acetate Chemical compound COC(=O)CC1(CC)OCCO1 VDRQCADWGSAXPV-UHFFFAOYSA-N 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- XNLIRUTVXHVUEA-UHFFFAOYSA-N tert-butyl 2-(1-hydroxycyclopentyl)acetate Chemical compound CC(C)(C)OC(=O)CC1(O)CCCC1 XNLIRUTVXHVUEA-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
- QPWMGMCPSFBYOU-UHFFFAOYSA-N (3-hydroxycyclopentyl) methanesulfonate Chemical compound CS(=O)(=O)OC1CCC(O)C1 QPWMGMCPSFBYOU-UHFFFAOYSA-N 0.000 description 2
- BWKAOFJDCPNWEC-UHFFFAOYSA-N (5-methyl-1,3-thiazol-2-yl)methanol Chemical compound CC1=CN=C(CO)S1 BWKAOFJDCPNWEC-UHFFFAOYSA-N 0.000 description 2
- HYOBIUULDPLKIE-UHFFFAOYSA-N (5-methylpyridin-2-yl)methanol Chemical compound CC1=CC=C(CO)N=C1 HYOBIUULDPLKIE-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LQCXNFVFODFRLN-UHFFFAOYSA-N 1-(3-hydroxybutyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]-7-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C[Si](C)(C)CCOCN1C=2C(=O)N(CCC(O)C)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 LQCXNFVFODFRLN-UHFFFAOYSA-N 0.000 description 2
- BQVLJXDTLXIXMN-UHFFFAOYSA-N 1-(3-hydroxybutyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC(O)C)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 BQVLJXDTLXIXMN-UHFFFAOYSA-N 0.000 description 2
- FVSQMDXZDMQDML-UHFFFAOYSA-N 1-(4-chlorophenyl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OC(C)C1=CC=C(Cl)C=C1 FVSQMDXZDMQDML-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- OKCQAPCXFRVFRB-UHFFFAOYSA-N 1-[2-(1-hydroxycyclopropyl)ethyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC3(O)CC3)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 OKCQAPCXFRVFRB-UHFFFAOYSA-N 0.000 description 2
- PXOZFWTULSYQAL-UHFFFAOYSA-N 1-[3-[tert-butyl(dimethyl)silyl]oxy-2-hydroxypropyl]-7-[(4-chlorophenyl)methyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(O)CO[Si](C)(C)C(C)(C)C)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 PXOZFWTULSYQAL-UHFFFAOYSA-N 0.000 description 2
- HARITLZHGNEHDS-UHFFFAOYSA-N 1-[4-(bromomethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC=C(CBr)C=C1 HARITLZHGNEHDS-UHFFFAOYSA-N 0.000 description 2
- RIQQGAUEUXPHTK-UHFFFAOYSA-N 1-[7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxo-8-[3-(trifluoromethoxy)phenoxy]purin-1-yl]-n-methylmethanesulfonamide Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CS(=O)(=O)NC)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 RIQQGAUEUXPHTK-UHFFFAOYSA-N 0.000 description 2
- LCZUOKDVTBMCMX-UHFFFAOYSA-N 2,5-Dimethylpyrazine Chemical compound CC1=CN=C(C)C=N1 LCZUOKDVTBMCMX-UHFFFAOYSA-N 0.000 description 2
- KFEWUCOFCOAYQZ-UHFFFAOYSA-N 2,5-dimethyl-1-oxidopyridin-1-ium Chemical compound CC1=CC=C(C)[N+]([O-])=C1 KFEWUCOFCOAYQZ-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2,5-dimethylpyridine Chemical compound CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- CGNMMICVNJPYFY-UHFFFAOYSA-N 2-(1-hydroxycyclopentyl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1(O)CCCC1 CGNMMICVNJPYFY-UHFFFAOYSA-N 0.000 description 2
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
- ZQQLDLLYNATGDU-UHFFFAOYSA-N 2-(bromomethyl)-5-methyl-1,3-thiazole Chemical compound CC1=CN=C(CBr)S1 ZQQLDLLYNATGDU-UHFFFAOYSA-N 0.000 description 2
- DDGKEWIOOGLGAK-UHFFFAOYSA-N 2-(chloromethyl)-5-methylpyrazine Chemical compound CC1=CN=C(CCl)C=N1 DDGKEWIOOGLGAK-UHFFFAOYSA-N 0.000 description 2
- UADBLZFWTJHOJC-UHFFFAOYSA-N 2-(hydroxymethyl)cyclopentan-1-ol Chemical compound OCC1CCCC1O UADBLZFWTJHOJC-UHFFFAOYSA-N 0.000 description 2
- ZQXLMMBXCPBEIQ-UHFFFAOYSA-N 2-[2-(2-chloroethoxy)ethoxy]oxane Chemical compound ClCCOCCOC1CCCCO1 ZQXLMMBXCPBEIQ-UHFFFAOYSA-N 0.000 description 2
- WURIUGWQBLPGAL-UHFFFAOYSA-N 2-[3-(4-methyl-1,3-oxazol-2-yl)phenyl]acetonitrile Chemical compound CC1=COC(C=2C=C(CC#N)C=CC=2)=N1 WURIUGWQBLPGAL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- ZFLKNWKXPXDGTD-UHFFFAOYSA-N 2-[7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxo-8-[3-(trifluoromethoxy)phenoxy]purin-1-yl]-n,n-dimethylacetamide Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(=O)N(C)C)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 ZFLKNWKXPXDGTD-UHFFFAOYSA-N 0.000 description 2
- WEOWHBISJCXBIQ-UHFFFAOYSA-N 2-[7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxo-8-[3-(trifluoromethoxy)phenoxy]purin-1-yl]acetic acid Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(O)=O)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 WEOWHBISJCXBIQ-UHFFFAOYSA-N 0.000 description 2
- USLBEQCTFRRLHR-UHFFFAOYSA-N 2-[7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxo-8-[3-(trifluoromethyl)phenoxy]purin-1-yl]-n-methylacetamide Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(=O)NC)C(=O)N(C)C=2N=C1OC1=CC=CC(C(F)(F)F)=C1 USLBEQCTFRRLHR-UHFFFAOYSA-N 0.000 description 2
- XZLDTUNNWWHZCY-UHFFFAOYSA-N 2-amino-7-[(4-chlorophenyl)methyl]-3h-purin-6-one Chemical compound C1=2C(=O)NC(N)=NC=2N=CN1CC1=CC=C(Cl)C=C1 XZLDTUNNWWHZCY-UHFFFAOYSA-N 0.000 description 2
- FJPZHYAYNAUKKA-UHFFFAOYSA-N 2-bromo-5-methyl-1,3-thiazole Chemical compound CC1=CN=C(Br)S1 FJPZHYAYNAUKKA-UHFFFAOYSA-N 0.000 description 2
- RFHPMEOKJKCEFR-UHFFFAOYSA-N 2-cyclohexyloxyethanol Chemical compound OCCOC1CCCCC1 RFHPMEOKJKCEFR-UHFFFAOYSA-N 0.000 description 2
- UPLJXKFPVRLNHH-UHFFFAOYSA-N 3-(2-bromoethyl)-7-[(4-chlorophenyl)methyl]-1-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(C)C(=O)N(CCBr)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 UPLJXKFPVRLNHH-UHFFFAOYSA-N 0.000 description 2
- LIUCHRXQRHVSJI-UHFFFAOYSA-N 3-(2-hydroxyethoxy)benzaldehyde Chemical compound OCCOC1=CC=CC(C=O)=C1 LIUCHRXQRHVSJI-UHFFFAOYSA-N 0.000 description 2
- WBHXWMIFIZMHKS-UHFFFAOYSA-N 3-(morpholin-4-ylmethyl)phenol Chemical compound OC1=CC=CC(CN2CCOCC2)=C1 WBHXWMIFIZMHKS-UHFFFAOYSA-N 0.000 description 2
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- BJWFBCFBZNSAFO-UHFFFAOYSA-N 3-[3-(trifluoromethoxy)phenoxy]propan-1-ol Chemical compound OCCCOC1=CC=CC(OC(F)(F)F)=C1 BJWFBCFBZNSAFO-UHFFFAOYSA-N 0.000 description 2
- DCANXMAXOSVWNV-UHFFFAOYSA-N 3-[7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxo-8-[3-(trifluoromethoxy)phenoxy]purin-1-yl]propanenitrile Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCC#N)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 DCANXMAXOSVWNV-UHFFFAOYSA-N 0.000 description 2
- LKUMEFSWLVMDFW-UHFFFAOYSA-N 3-benzyl-7-[(4-chlorophenyl)methyl]-1-methyl-8-[3-(trifluoromethyl)phenoxy]purine-2,6-dione Chemical compound C1=2N=C(OC=3C=C(C=CC=3)C(F)(F)F)N(CC=3C=CC(Cl)=CC=3)C=2C(=O)N(C)C(=O)N1CC1=CC=CC=C1 LKUMEFSWLVMDFW-UHFFFAOYSA-N 0.000 description 2
- LQZXPEQGLNELFN-UHFFFAOYSA-N 3-methyl-1-[3-(oxan-2-yloxy)propyl]-8-[3-(trifluoromethoxy)phenoxy]-7-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C[Si](C)(C)CCOCN1C=2C(=O)N(CCCOC3OCCCC3)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 LQZXPEQGLNELFN-UHFFFAOYSA-N 0.000 description 2
- XEONQQZVVDBWRY-UHFFFAOYSA-N 3-methyl-8-[3-(trifluoromethoxy)phenoxy]-1-(3,3,3-trifluoropropyl)-7-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C[Si](C)(C)CCOCN1C=2C(=O)N(CCC(F)(F)F)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 XEONQQZVVDBWRY-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- RBFVGQWGOARJRU-UHFFFAOYSA-N 4-bromo-2-methylbutan-2-ol Chemical compound CC(C)(O)CCBr RBFVGQWGOARJRU-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
- GHFAUTJRYNSYHR-UHFFFAOYSA-N 5-(chloromethyl)-2-methylpyrimidine Chemical compound CC1=NC=C(CCl)C=N1 GHFAUTJRYNSYHR-UHFFFAOYSA-N 0.000 description 2
- BOAXUHSQXGCIJT-UHFFFAOYSA-N 6-amino-3-[(4-methoxyphenyl)methyl]-1-methyl-5-nitrosopyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C)C(N)=C(N=O)C1=O BOAXUHSQXGCIJT-UHFFFAOYSA-N 0.000 description 2
- JGAVPFNFAUWIJY-UHFFFAOYSA-N 6-amino-3-methyl-1h-pyrimidine-2,4-dione Chemical compound CN1C(=O)C=C(N)NC1=O JGAVPFNFAUWIJY-UHFFFAOYSA-N 0.000 description 2
- WVZINIZPFWBLDK-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(2,3-dihydroxypropyl)-3-methyl-8-[3-(trifluoromethyl)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(O)CO)C(=O)N(C)C=2N=C1OC1=CC=CC(C(F)(F)F)=C1 WVZINIZPFWBLDK-UHFFFAOYSA-N 0.000 description 2
- NLGMNRKUWXKOGK-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(3-hydroxybutyl)-3-methyl-8-(6-methylpyridin-3-yl)oxypurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCC(O)C)C(=O)N(C)C=2N=C1OC1=CC=C(C)N=C1 NLGMNRKUWXKOGK-UHFFFAOYSA-N 0.000 description 2
- BVAREGPEIKZCLQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-[2-(1,3-dioxoisoindol-2-yl)ethyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCN3C(C4=CC=CC=C4C3=O)=O)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 BVAREGPEIKZCLQ-UHFFFAOYSA-N 0.000 description 2
- FATVPFGNSIMMPH-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-[2-(2-ethyl-1,3-dioxolan-2-yl)ethyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound O=C1N(C)C=2N=C(OC=3C=C(OC(F)(F)F)C=CC=3)N(CC=3C=CC(Cl)=CC=3)C=2C(=O)N1CCC1(CC)OCCO1 FATVPFGNSIMMPH-UHFFFAOYSA-N 0.000 description 2
- DZLBUIXGZMJMAQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-[3-(dimethylamino)-2-hydroxypropyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(O)CN(C)C)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 DZLBUIXGZMJMAQ-UHFFFAOYSA-N 0.000 description 2
- IMDATFDRTWHGKI-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-[3-(dimethylamino)-2-oxopropyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione;hydrochloride Chemical compound Cl.C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(=O)CN(C)C)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 IMDATFDRTWHGKI-UHFFFAOYSA-N 0.000 description 2
- MBIVUGBBYWAPPS-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-ethyl-3-methyl-8-[3-(trifluoromethyl)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC)C(=O)N(C)C=2N=C1OC1=CC=CC(C(F)(F)F)=C1 MBIVUGBBYWAPPS-UHFFFAOYSA-N 0.000 description 2
- VLZUKGHYXWRIDM-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-1-(1,2-oxazol-5-ylmethyl)-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC=3ON=CC=3)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 VLZUKGHYXWRIDM-UHFFFAOYSA-N 0.000 description 2
- FALPDPUPHALEDF-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-1-(oxiran-2-ylmethyl)-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC3OC3)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 FALPDPUPHALEDF-UHFFFAOYSA-N 0.000 description 2
- LQNCYYRMLULJHB-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-1-[(5-methyl-1,2-oxazol-3-yl)methyl]-8-[3-(trifluoromethyl)phenoxy]purine-2,6-dione Chemical compound O1C(C)=CC(CN2C(C=3N(CC=4C=CC(Cl)=CC=4)C(OC=4C=C(C=CC=4)C(F)(F)F)=NC=3N(C)C2=O)=O)=N1 LQNCYYRMLULJHB-UHFFFAOYSA-N 0.000 description 2
- DBYIFLUYUFWLMW-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C1CN(C)CCN1C(=O)CN1C(=O)C(N(CC=2C=CC(Cl)=CC=2)C(OC=2C=C(OC(F)(F)F)C=CC=2)=N2)=C2N(C)C1=O DBYIFLUYUFWLMW-UHFFFAOYSA-N 0.000 description 2
- IIZGCHOGLFNGOT-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-1-[2-(4-methylpiperazin-1-yl)ethyl]-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C1CN(C)CCN1CCN1C(=O)C(N(CC=2C=CC(Cl)=CC=2)C(OC=2C=C(OC(F)(F)F)C=CC=2)=N2)=C2N(C)C1=O IIZGCHOGLFNGOT-UHFFFAOYSA-N 0.000 description 2
- TZBQPHNYUCPJGZ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-1-[3-(oxan-2-yloxy)propyl]-8-sulfanylidene-9h-purine-2,6-dione Chemical compound C1=2C(=O)N(CCCOC3OCCCC3)C(=O)N(C)C=2N=C(S)N1CC1=CC=C(Cl)C=C1 TZBQPHNYUCPJGZ-UHFFFAOYSA-N 0.000 description 2
- AUJHDVNLKRHIJR-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxopurine-8-sulfonyl chloride Chemical compound C1=2C(=O)NC(=O)N(C)C=2N=C(S(Cl)(=O)=O)N1CC1=CC=C(Cl)C=C1 AUJHDVNLKRHIJR-UHFFFAOYSA-N 0.000 description 2
- OXNAXQUMBILEGB-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]-1-(3,3,3-trifluoropropyl)purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCC(F)(F)F)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 OXNAXQUMBILEGB-UHFFFAOYSA-N 0.000 description 2
- DKFYSCUPRLIDDT-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3h-purine-2,6-dione Chemical compound C1=CC(Cl)=CC=C1CN1C(C(=O)NC(=O)N2)=C2N=C1 DKFYSCUPRLIDDT-UHFFFAOYSA-N 0.000 description 2
- SZNVRYHBMCJXEP-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[4-chloro-3-(trifluoromethyl)phenoxy]-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1OC1=CC=C(Cl)C(C(F)(F)F)=C1 SZNVRYHBMCJXEP-UHFFFAOYSA-N 0.000 description 2
- ZSWNNXRBHKNOMY-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]-1-[(4-methoxyphenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(N(CC=2C=CC(Cl)=CC=2)C(CC=2C(=CC=C(OC(F)(F)F)C=2)F)=N2)=C2N(C)C1=O ZSWNNXRBHKNOMY-UHFFFAOYSA-N 0.000 description 2
- RTNPMFYUYYYPCP-UHFFFAOYSA-N 7-benzyl-1-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-8-chloro-3-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C1=2C(=O)N(CCCO[Si](C)(C)C(C)(C)C)C(=O)N(COCC[Si](C)(C)C)C=2N=C(Cl)N1CC1=CC=CC=C1 RTNPMFYUYYYPCP-UHFFFAOYSA-N 0.000 description 2
- HQHCZURAVYVXRE-UHFFFAOYSA-N 7-benzyl-8-[3-(trifluoromethoxy)phenoxy]-3-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)NC(=O)N(COCC[Si](C)(C)C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 HQHCZURAVYVXRE-UHFFFAOYSA-N 0.000 description 2
- VXDZZRYETRAIFK-UHFFFAOYSA-N 7-benzyl-8-[3-(trifluoromethoxy)phenoxy]-3h-purine-2,6-dione Chemical compound FC(F)(F)OC1=CC=CC(OC=2N(C=3C(=O)NC(=O)NC=3N=2)CC=2C=CC=CC=2)=C1 VXDZZRYETRAIFK-UHFFFAOYSA-N 0.000 description 2
- MVGKCAVFSGOXKR-UHFFFAOYSA-N 7-benzyl-8-ethoxy-3-ethyl-1-(3-hydroxypropyl)purine-2,6-dione Chemical compound CCOC1=NC=2N(CC)C(=O)N(CCCO)C(=O)C=2N1CC1=CC=CC=C1 MVGKCAVFSGOXKR-UHFFFAOYSA-N 0.000 description 2
- UHYMTBSDNVXYSA-UHFFFAOYSA-N 8-[3,5-bis(trifluoromethyl)phenoxy]-7-[(4-chlorophenyl)methyl]-3-ethyl-1-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(C)C(=O)N(CC)C=2N=C1OC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UHYMTBSDNVXYSA-UHFFFAOYSA-N 0.000 description 2
- YZOYHDZNGNCDOC-UHFFFAOYSA-N 8-amino-7-[(4-chlorophenyl)methyl]-3-methyl-1-[3-(oxan-2-yloxy)propyl]purine-2,6-dione Chemical compound C1=2C(=O)N(CCCOC3OCCCC3)C(=O)N(C)C=2N=C(N)N1CC1=CC=C(Cl)C=C1 YZOYHDZNGNCDOC-UHFFFAOYSA-N 0.000 description 2
- LIPOSNJLPGAOQZ-UHFFFAOYSA-N 8-bromo-3-methyl-1-[3-(oxan-2-yloxy)propyl]-7-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound O=C1N(C)C=2N=C(Br)N(COCC[Si](C)(C)C)C=2C(=O)N1CCCOC1CCCCO1 LIPOSNJLPGAOQZ-UHFFFAOYSA-N 0.000 description 2
- QMJODVNXZONJNP-UHFFFAOYSA-N 8-bromo-7-[(4-chlorophenyl)methyl]-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C1=2C(=O)N(CCCO)C(=O)N(C)C=2N=C(Br)N1CC1=CC=C(Cl)C=C1 QMJODVNXZONJNP-UHFFFAOYSA-N 0.000 description 2
- RXNKGCAWQYNOJN-UHFFFAOYSA-N 8-bromo-7-[(4-chlorophenyl)methyl]-3-methyl-1-[2-(oxan-2-yloxy)ethyl]purine-2,6-dione Chemical compound C1=2C(=O)N(CCOC3OCCCC3)C(=O)N(C)C=2N=C(Br)N1CC1=CC=C(Cl)C=C1 RXNKGCAWQYNOJN-UHFFFAOYSA-N 0.000 description 2
- KVACEBLEMNRVHA-UHFFFAOYSA-N 8-bromo-7-ethyl-3-methyl-1-[3-(oxan-2-yloxy)propyl]purine-2,6-dione Chemical compound O=C1C=2N(CC)C(Br)=NC=2N(C)C(=O)N1CCCOC1CCCCO1 KVACEBLEMNRVHA-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102000003564 TRPC7 Human genes 0.000 description 2
- 101150095096 TRPM2 gene Proteins 0.000 description 2
- 102000003610 TRPM8 Human genes 0.000 description 2
- 102000003566 TRPV1 Human genes 0.000 description 2
- 102000003565 TRPV2 Human genes 0.000 description 2
- 102000003568 TRPV3 Human genes 0.000 description 2
- 102000003567 TRPV4 Human genes 0.000 description 2
- 101150098315 TRPV4 gene Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 2
- 101150033973 Trpc7 gene Proteins 0.000 description 2
- 101150111302 Trpm8 gene Proteins 0.000 description 2
- 101150016206 Trpv1 gene Proteins 0.000 description 2
- 101150077905 Trpv2 gene Proteins 0.000 description 2
- 101150043371 Trpv3 gene Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940125684 antimigraine agent Drugs 0.000 description 2
- 239000002282 antimigraine agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- WVMITIFDHVQLPI-UHFFFAOYSA-N ethyl 2-(2-hydroxypropylamino)-2-oxoacetate Chemical compound CCOC(=O)C(=O)NCC(C)O WVMITIFDHVQLPI-UHFFFAOYSA-N 0.000 description 2
- ITJNGUUXCZIMTD-UHFFFAOYSA-N ethyl 2-oxo-2-(2-oxopropylamino)acetate Chemical compound CCOC(=O)C(=O)NCC(C)=O ITJNGUUXCZIMTD-UHFFFAOYSA-N 0.000 description 2
- SROLLGNCTWNCAY-UHFFFAOYSA-N ethyl 3-[(4-chlorophenyl)methyl]-5-[(3-phenylmethoxycyclobutyl)carbamoylamino]imidazole-4-carboxylate Chemical compound N1=CN(CC=2C=CC(Cl)=CC=2)C(C(=O)OCC)=C1NC(=O)NC(C1)CC1OCC1=CC=CC=C1 SROLLGNCTWNCAY-UHFFFAOYSA-N 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960001419 fenoprofen Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000001282 glomerular podocyte Anatomy 0.000 description 2
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- DQYYUAAQJNSOTP-UHFFFAOYSA-N n-[2-[7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxo-8-[3-(trifluoromethoxy)phenoxy]purin-1-yl]ethyl]propane-2-sulfonamide Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCNS(=O)(=O)C(C)C)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 DQYYUAAQJNSOTP-UHFFFAOYSA-N 0.000 description 2
- VPJOYKNJFWVCCA-UHFFFAOYSA-N n-[4-amino-1-[(4-methoxyphenyl)methyl]-3-methyl-2,6-dioxopyrimidin-5-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C)C(N)=C(NC(=O)CC=2C=C(OC(F)(F)F)C=CC=2)C1=O VPJOYKNJFWVCCA-UHFFFAOYSA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 210000001032 spinal nerve Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000011706 wistar kyoto rat Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ULIYQAUQKZDZOX-UHFFFAOYSA-N 1,1,1-trifluoro-3-iodopropane Chemical compound FC(F)(F)CCI ULIYQAUQKZDZOX-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- QOOSRUMHBCVQFK-UHFFFAOYSA-N 1,2-oxazol-5-ylmethanol Chemical compound OCC1=CC=NO1 QOOSRUMHBCVQFK-UHFFFAOYSA-N 0.000 description 1
- MIIQJAUWHSUTIT-UHFFFAOYSA-N 1,2-oxazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=NO1 MIIQJAUWHSUTIT-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- KYVCFGVPQGGDRF-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-3-methyl-7-[(5-methylpyridin-2-yl)methyl]-8-[[3-(trifluoromethoxy)phenyl]methyl]purine-2,6-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(N(CC=2N=CC(C)=CC=2)C(CC=2C=C(OC(F)(F)F)C=CC=2)=N2)=C2N(C)C1=O KYVCFGVPQGGDRF-UHFFFAOYSA-N 0.000 description 1
- VVTQRUFFDXVIIX-UHFFFAOYSA-N 1-[3-[tert-butyl(dimethyl)silyl]oxy-2-methoxypropyl]-7-[(4-chlorophenyl)methyl]-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(CO[Si](C)(C)C(C)(C)C)OC)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 VVTQRUFFDXVIIX-UHFFFAOYSA-N 0.000 description 1
- JAXUXCBIHWEDAP-UHFFFAOYSA-N 1-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-3-methyl-7-(3-methylbutyl)purine-2,6-dione Chemical compound [Si](C)(C)(C(C)(C)C)OCCCN1C(N(C=2N=CN(C=2C1=O)CCC(C)C)C)=O JAXUXCBIHWEDAP-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- FOLYKNXDLNPWGC-UHFFFAOYSA-N 1-chloro-3-methoxypropan-2-ol Chemical compound COCC(O)CCl FOLYKNXDLNPWGC-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- UQZXQSQWKJZHCD-UHFFFAOYSA-N 1-iodo-3-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=CC(I)=C1 UQZXQSQWKJZHCD-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- WVUHHPQQQLBMOE-UHFFFAOYSA-N 2,5-Dimethyl-1,3-thiazole Chemical compound CC1=CN=C(C)S1 WVUHHPQQQLBMOE-UHFFFAOYSA-N 0.000 description 1
- 239000001934 2,5-dimethylpyrazine Substances 0.000 description 1
- JTKYFAWAIZTVID-UHFFFAOYSA-N 2-(1-hydroxycyclobutyl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1(O)CCC1 JTKYFAWAIZTVID-UHFFFAOYSA-N 0.000 description 1
- CHZXTOCAICMPQR-UHFFFAOYSA-N 2-(2-bromoethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCBr)C(=O)C2=C1 CHZXTOCAICMPQR-UHFFFAOYSA-N 0.000 description 1
- LECMBPWEOVZHKN-UHFFFAOYSA-N 2-(2-chloroethoxy)ethanol Chemical compound OCCOCCCl LECMBPWEOVZHKN-UHFFFAOYSA-N 0.000 description 1
- FCHYIMQJCGYDPR-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethyl methanesulfonate Chemical compound COCCOCCOS(C)(=O)=O FCHYIMQJCGYDPR-UHFFFAOYSA-N 0.000 description 1
- GARMQVNIPCKVOJ-UHFFFAOYSA-N 2-(3-chlorophenoxy)ethanol Chemical compound OCCOC1=CC=CC(Cl)=C1 GARMQVNIPCKVOJ-UHFFFAOYSA-N 0.000 description 1
- FDBXUXVQIOQYIX-UHFFFAOYSA-N 2-(3-methylphenoxy)ethanol Chemical compound CC1=CC=CC(OCCO)=C1 FDBXUXVQIOQYIX-UHFFFAOYSA-N 0.000 description 1
- MXOPKPMEGUYUCV-UHFFFAOYSA-N 2-(chloromethyl)-5-methylpyridine Chemical compound CC1=CC=C(CCl)N=C1 MXOPKPMEGUYUCV-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- LKEGEXNDRNKGTO-UHFFFAOYSA-N 2-[2-(trifluoromethoxy)phenoxy]ethanol Chemical compound OCCOC1=CC=CC=C1OC(F)(F)F LKEGEXNDRNKGTO-UHFFFAOYSA-N 0.000 description 1
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 1
- PYCWSPHSXHTRQT-UHFFFAOYSA-N 2-[2-fluoro-5-(trifluoromethoxy)phenyl]acetic acid Chemical compound OC(=O)CC1=CC(OC(F)(F)F)=CC=C1F PYCWSPHSXHTRQT-UHFFFAOYSA-N 0.000 description 1
- NUNUAFJJYCNGFX-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]ethanol Chemical compound OCCOC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NUNUAFJJYCNGFX-UHFFFAOYSA-N 0.000 description 1
- NFZQVADYFXRRPM-UHFFFAOYSA-N 2-[3-(trifluoromethoxy)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(OC(F)(F)F)=C1 NFZQVADYFXRRPM-UHFFFAOYSA-N 0.000 description 1
- XZFROFAISZKBSS-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenoxy]ethanol Chemical compound OCCOC1=CC=CC(C(F)(F)F)=C1 XZFROFAISZKBSS-UHFFFAOYSA-N 0.000 description 1
- SCDMIAUXJRMTPH-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenoxy]ethanol Chemical compound OCCOC1=CC=C(OC(F)(F)F)C=C1 SCDMIAUXJRMTPH-UHFFFAOYSA-N 0.000 description 1
- HIXOEOKYOAKGEJ-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenoxy]ethanol Chemical compound OCCOC1=CC=C(Cl)C(C(F)(F)F)=C1 HIXOEOKYOAKGEJ-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-UHFFFAOYSA-N 2-amino-2-phenylethanol Chemical compound OCC(N)C1=CC=CC=C1 IJXJGQCXFSSHNL-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-WUZBBMAGSA-N 2-amino-9-[(2r,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@@H]1O NYHBQMYGNKIUIF-WUZBBMAGSA-N 0.000 description 1
- DDOQBQRIEWHWBT-UHFFFAOYSA-N 2-azaniumyl-4-phosphonobutanoate Chemical compound OC(=O)C(N)CCP(O)(O)=O DDOQBQRIEWHWBT-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- NMGIXZFBQPETOK-UHFFFAOYSA-N 2-methylpyrimidine-5-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)C=N1 NMGIXZFBQPETOK-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- HDBGBTNNPRCVND-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-ol Chemical compound OCCC(F)(F)F HDBGBTNNPRCVND-UHFFFAOYSA-N 0.000 description 1
- DPYRAILBOJTIRV-UHFFFAOYSA-N 3-(cyanomethyl)benzamide Chemical compound NC(=O)C1=CC=CC(CC#N)=C1 DPYRAILBOJTIRV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SNYGRFCCIAUZDF-UHFFFAOYSA-N 3-benzyl-7-[(4-chlorophenyl)methyl]-1-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C1=2N=C(OC=3C=C(OC(F)(F)F)C=CC=3)N(CC=3C=CC(Cl)=CC=3)C=2C(=O)N(C)C(=O)N1CC1=CC=CC=C1 SNYGRFCCIAUZDF-UHFFFAOYSA-N 0.000 description 1
- GXXDXHZVILHXBM-UHFFFAOYSA-N 3-benzyl-8-chloro-7-[(4-chlorophenyl)methyl]-1-methylpurine-2,6-dione Chemical compound C1=2N=C(Cl)N(CC=3C=CC(Cl)=CC=3)C=2C(=O)N(C)C(=O)N1CC1=CC=CC=C1 GXXDXHZVILHXBM-UHFFFAOYSA-N 0.000 description 1
- ZJQWXXSZXSTKHW-UHFFFAOYSA-N 3-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1.OOC(=O)C1=CC=CC(Cl)=C1 ZJQWXXSZXSTKHW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- VKPLPDIMEREJJF-UHFFFAOYSA-N 3-methoxybenzamide Chemical compound COC1=CC=CC(C(N)=O)=C1 VKPLPDIMEREJJF-UHFFFAOYSA-N 0.000 description 1
- JAOYVXWDFSHPHQ-UHFFFAOYSA-N 3-methyl-1-[2-[2-(oxan-2-yloxy)ethoxy]ethyl]-8-[3-(trifluoromethoxy)phenoxy]-7-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C[Si](C)(C)CCOCN1C=2C(=O)N(CCOCCOC3OCCCC3)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 JAOYVXWDFSHPHQ-UHFFFAOYSA-N 0.000 description 1
- QTAAQBOVEGUWPJ-UHFFFAOYSA-N 3-methyl-1-[3-(oxan-2-yloxy)propyl]-8-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]-7-(2-trimethylsilylethoxymethyl)purine-2,6-dione Chemical compound C[Si](C)(C)CCOCN1C=2C(=O)N(CCCOC3OCCCC3)C(=O)N(C)C=2N=C1OCCOC1=CC=CC(OC(F)(F)F)=C1 QTAAQBOVEGUWPJ-UHFFFAOYSA-N 0.000 description 1
- XPLGZKDOGAUOJI-UHFFFAOYSA-N 3-methyl-8-[3-(trifluoromethoxy)phenoxy]-7H-purine-2,6-dione Chemical compound C1=C(OC=2NC3=C(N(C(=O)NC3=O)C)N=2)C=C(OC(F)(F)F)C=C1 XPLGZKDOGAUOJI-UHFFFAOYSA-N 0.000 description 1
- GMSNIKWWOQHZGF-UHFFFAOYSA-N 3-methyl-9H-xanthine Chemical compound O=C1NC(=O)N(C)C2=C1N=CN2 GMSNIKWWOQHZGF-UHFFFAOYSA-N 0.000 description 1
- YNNOFVDQHAHVFG-UHFFFAOYSA-N 3-phenylmethoxycyclobutane-1-carboxylic acid Chemical compound C1C(C(=O)O)CC1OCC1=CC=CC=C1 YNNOFVDQHAHVFG-UHFFFAOYSA-N 0.000 description 1
- VKRFUGHXKNNIJO-UHFFFAOYSA-N 4,4,4-trifluorobutan-1-ol Chemical compound OCCCC(F)(F)F VKRFUGHXKNNIJO-UHFFFAOYSA-N 0.000 description 1
- IMWQVSSRLXGHOO-UHFFFAOYSA-N 4,4,4-trifluorobutyl methanesulfonate Chemical compound CS(=O)(=O)OCCCC(F)(F)F IMWQVSSRLXGHOO-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- ZLFPIEUWXNRPNM-UHFFFAOYSA-N 4-chloro-3-(trifluoromethyl)phenol Chemical compound OC1=CC=C(Cl)C(C(F)(F)F)=C1 ZLFPIEUWXNRPNM-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- WJVQJXVMLRGNGA-UHFFFAOYSA-N 5-bromopentan-1-ol Chemical compound OCCCCCBr WJVQJXVMLRGNGA-UHFFFAOYSA-N 0.000 description 1
- BXZSBDDOYIWMGC-UHFFFAOYSA-N 5-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(F)=C1 BXZSBDDOYIWMGC-UHFFFAOYSA-N 0.000 description 1
- GZLZRPNUDBIQBM-UHFFFAOYSA-N 6-amino-1-methylpyrimidine-2,4-dione Chemical compound CN1C(N)=CC(=O)NC1=O GZLZRPNUDBIQBM-UHFFFAOYSA-N 0.000 description 1
- LNDZXOWGUAIUBG-UHFFFAOYSA-N 6-aminouracil Chemical compound NC1=CC(=O)NC(=O)N1 LNDZXOWGUAIUBG-UHFFFAOYSA-N 0.000 description 1
- WFMKQUUAWRLGIE-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(2-hydroxy-3-methoxypropyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(O)COC)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 WFMKQUUAWRLGIE-UHFFFAOYSA-N 0.000 description 1
- NBCSSMPHIFXIDF-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(2-hydroxyethyl)-3-methyl-8-[3-(trifluoromethyl)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCO)C(=O)N(C)C=2N=C1OC1=CC=CC(C(F)(F)F)=C1 NBCSSMPHIFXIDF-UHFFFAOYSA-N 0.000 description 1
- PRJHEJGMSOBHTO-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(3-hydroxypropyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 PRJHEJGMSOBHTO-UHFFFAOYSA-N 0.000 description 1
- SBEYWUQNLIMSAX-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(3-methoxy-2-oxopropyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CC(=O)COC)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 SBEYWUQNLIMSAX-UHFFFAOYSA-N 0.000 description 1
- IMNCEAPDNXBJBA-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(3-phenylmethoxycyclobutyl)-3h-purine-2,6-dione Chemical compound C1=CC(Cl)=CC=C1CN1C(C(=O)N(C2CC(C2)OCC=2C=CC=CC=2)C(=O)N2)=C2N=C1 IMNCEAPDNXBJBA-UHFFFAOYSA-N 0.000 description 1
- VXKYLUJHRPDBOQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(4-hydroxybutyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCCO)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 VXKYLUJHRPDBOQ-UHFFFAOYSA-N 0.000 description 1
- DCWPUCPXASMQQU-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(5-hydroxypentyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCCCO)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 DCWPUCPXASMQQU-UHFFFAOYSA-N 0.000 description 1
- FYSHSWAGIOTEIU-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-methyl-3-(1,2-oxazol-5-ylmethyl)-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C1=2N=C(OC=3C=C(OC(F)(F)F)C=CC=3)N(CC=3C=CC(Cl)=CC=3)C=2C(=O)N(C)C(=O)N1CC1=CC=NO1 FYSHSWAGIOTEIU-UHFFFAOYSA-N 0.000 description 1
- UOWAAOPONQUJMN-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-methyl-3-(2-oxopropyl)-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(C)C(=O)N(CC(=O)C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 UOWAAOPONQUJMN-UHFFFAOYSA-N 0.000 description 1
- HWTCGSWAEPWDRC-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-methyl-3-(pyridin-2-ylmethyl)-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C1=2N=C(OC=3C=C(OC(F)(F)F)C=CC=3)N(CC=3C=CC(Cl)=CC=3)C=2C(=O)N(C)C(=O)N1CC1=CC=CC=N1 HWTCGSWAEPWDRC-UHFFFAOYSA-N 0.000 description 1
- PKYUCGHKCNRFIA-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-methyl-3-(pyridin-2-ylmethyl)-8-[3-(trifluoromethyl)phenoxy]purine-2,6-dione Chemical compound C1=2N=C(OC=3C=C(C=CC=3)C(F)(F)F)N(CC=3C=CC(Cl)=CC=3)C=2C(=O)N(C)C(=O)N1CC1=CC=CC=N1 PKYUCGHKCNRFIA-UHFFFAOYSA-N 0.000 description 1
- ZLAARJUJQNFGOY-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-methyl-3-(pyridin-4-ylmethyl)-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C1=2N=C(OC=3C=C(OC(F)(F)F)C=CC=3)N(CC=3C=CC(Cl)=CC=3)C=2C(=O)N(C)C(=O)N1CC1=CC=NC=C1 ZLAARJUJQNFGOY-UHFFFAOYSA-N 0.000 description 1
- TXVZILOHNDZOIA-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-methyl-3-propyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(C)C(=O)N(CCC)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 TXVZILOHNDZOIA-UHFFFAOYSA-N 0.000 description 1
- DHXGHODRCDGOIQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-methyl-8-[3-(trifluoromethoxy)phenoxy]-3h-purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(C)C(=O)NC=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 DHXGHODRCDGOIQ-UHFFFAOYSA-N 0.000 description 1
- UAYQIXADTVXSEB-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-[2-(2-hydroxyethoxy)ethyl]-1-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(C)C(=O)N(CCOCCO)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 UAYQIXADTVXSEB-UHFFFAOYSA-N 0.000 description 1
- IJHLHQJYZHWTSD-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-ethyl-1-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(C)C(=O)N(CC)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 IJHLHQJYZHWTSD-UHFFFAOYSA-N 0.000 description 1
- WMCCXHHMYINZMT-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-ethyl-1-methyl-8-[3-(trifluoromethyl)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(C)C(=O)N(CC)C=2N=C1OC1=CC=CC(C(F)(F)F)=C1 WMCCXHHMYINZMT-UHFFFAOYSA-N 0.000 description 1
- ZTRCRUCTKLESFS-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-1-(3-phenylmethoxycyclobutyl)purine-2,6-dione Chemical compound C1=2C(=O)N(C3CC(C3)OCC=3C=CC=CC=3)C(=O)N(C)C=2N=CN1CC1=CC=C(Cl)C=C1 ZTRCRUCTKLESFS-UHFFFAOYSA-N 0.000 description 1
- STLDXONESIDZNA-UHFFFAOYSA-N 7-benzyl-8-bromo-1-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-3-methylpurine-2,6-dione Chemical compound C1=2C(=O)N(CCCO[Si](C)(C)C(C)(C)C)C(=O)N(C)C=2N=C(Br)N1CC1=CC=CC=C1 STLDXONESIDZNA-UHFFFAOYSA-N 0.000 description 1
- BBEYAHRURAKGHU-UHFFFAOYSA-N 8-[3,5-bis(trifluoromethyl)phenoxy]-7-[(4-chlorophenyl)methyl]-1-[2-(2-hydroxyethoxy)ethyl]-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCOCCO)C(=O)N(C)C=2N=C1OC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BBEYAHRURAKGHU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NFYZIVVKIWJMPJ-UHFFFAOYSA-N 8-azido-7-[(4-chlorophenyl)methyl]-3-methyl-1-[3-(oxan-2-yloxy)propyl]purine-2,6-dione Chemical compound C1=2C(=O)N(CCCOC3OCCCC3)C(=O)N(C)C=2N=C(N=[N+]=[N-])N1CC1=CC=C(Cl)C=C1 NFYZIVVKIWJMPJ-UHFFFAOYSA-N 0.000 description 1
- PXEJEGSVXQVGBG-UHFFFAOYSA-N 8-bromo-1-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-7-[(4-chlorophenyl)methyl]-3-methylpurine-2,6-dione Chemical compound C1=2C(=O)N(CCCO[Si](C)(C)C(C)(C)C)C(=O)N(C)C=2N=C(Br)N1CC1=CC=C(Cl)C=C1 PXEJEGSVXQVGBG-UHFFFAOYSA-N 0.000 description 1
- DBQYZQFOQFOBHU-UHFFFAOYSA-N 8-bromo-3-methyl-7-(3-methylbutyl)purine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=C(Br)N2CCC(C)C DBQYZQFOQFOBHU-UHFFFAOYSA-N 0.000 description 1
- SGFDLDDDWWUBEY-UHFFFAOYSA-N 8-bromo-7-[(4-chlorophenyl)methyl]-1-[2-(1-hydroxycyclopropyl)ethyl]-3-methylpurine-2,6-dione Chemical compound C1=2C(=O)N(CCC3(O)CC3)C(=O)N(C)C=2N=C(Br)N1CC1=CC=C(Cl)C=C1 SGFDLDDDWWUBEY-UHFFFAOYSA-N 0.000 description 1
- DCPRNKBHQWAUTQ-UHFFFAOYSA-N 8-bromo-7-[(4-chlorophenyl)methyl]-3-methyl-1-[2-[2-(oxan-2-yloxy)ethoxy]ethyl]purine-2,6-dione Chemical compound C1=2C(=O)N(CCOCCOC3OCCCC3)C(=O)N(C)C=2N=C(Br)N1CC1=CC=C(Cl)C=C1 DCPRNKBHQWAUTQ-UHFFFAOYSA-N 0.000 description 1
- CWEVNUPQVALEHL-UHFFFAOYSA-N 8-bromo-7-ethyl-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCO)C(=O)C2=C1N=C(Br)N2CC CWEVNUPQVALEHL-UHFFFAOYSA-N 0.000 description 1
- OAIZADSULTWOJX-UHFFFAOYSA-N 8-chloro-7-[(4-chlorophenyl)methyl]-3-methyl-1-(3-phenylmethoxycyclobutyl)purine-2,6-dione Chemical compound C1=2C(=O)N(C3CC(C3)OCC=3C=CC=CC=3)C(=O)N(C)C=2N=C(Cl)N1CC1=CC=C(Cl)C=C1 OAIZADSULTWOJX-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- UYCANRJDZKZEMS-UHFFFAOYSA-N C1CCOC(C1)OCCOCC(=O)Cl Chemical compound C1CCOC(C1)OCCOCC(=O)Cl UYCANRJDZKZEMS-UHFFFAOYSA-N 0.000 description 1
- ZVCNKRKEHICRBY-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OC1=NC=C2C(=NC=N2)N1Br Chemical compound CC(C)(C)[Si](C)(C)OC1=NC=C2C(=NC=N2)N1Br ZVCNKRKEHICRBY-UHFFFAOYSA-N 0.000 description 1
- VXZVHEUJRMBLII-UHFFFAOYSA-N CCC(CCN1CN(C2=NC(N(C2=C1)CC3=CC=C(C=C3)Cl)OC4=CC(=CC=C4)OC(F)(F)F)C)O Chemical compound CCC(CCN1CN(C2=NC(N(C2=C1)CC3=CC=C(C=C3)Cl)OC4=CC(=CC=C4)OC(F)(F)F)C)O VXZVHEUJRMBLII-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KYDUJVYQVIYBDA-UHFFFAOYSA-N ClC1=CC=C(CN2C(N=C3N(CNC=C23)C)OC2=CC(=CC=C2)OC(F)(F)F)C=C1 Chemical compound ClC1=CC=C(CN2C(N=C3N(CNC=C23)C)OC2=CC(=CC=C2)OC(F)(F)F)C=C1 KYDUJVYQVIYBDA-UHFFFAOYSA-N 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000025967 Dissociative Identity disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 206010061225 Limb injury Diseases 0.000 description 1
- 206010061599 Lower limb fracture Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- LUSOBWUVKXVJAE-UHFFFAOYSA-N N-[7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxo-8-[3-(trifluoromethoxy)phenoxy]purin-1-yl]methanesulfonamide Chemical compound CS(=O)(=O)NN1C(N(C=2N=C(N(C=2C1=O)CC1=CC=C(C=C1)Cl)OC1=CC(=CC=C1)OC(F)(F)F)C)=O LUSOBWUVKXVJAE-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- LEHBZKKNBLZAHX-UHFFFAOYSA-N O=C(C1=C(N2OC(C=CC=C3)=C3OC(F)(F)F)N=CN1)NC2=O Chemical compound O=C(C1=C(N2OC(C=CC=C3)=C3OC(F)(F)F)N=CN1)NC2=O LEHBZKKNBLZAHX-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 101100100680 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trp4 gene Proteins 0.000 description 1
- 208000000810 Separation Anxiety Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000002628 TRPC Cation Channels Human genes 0.000 description 1
- 108010082847 TRPC Cation Channels Proteins 0.000 description 1
- 102000003627 TRPC1 Human genes 0.000 description 1
- 101150017559 TRPC1 gene Proteins 0.000 description 1
- 102000003622 TRPC4 Human genes 0.000 description 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 101150099990 Trpc4 gene Proteins 0.000 description 1
- 206010045171 Tumour pain Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010047095 Vascular pain Diseases 0.000 description 1
- YAINYZJQSQEGND-UHFFFAOYSA-N [1-(hydroxymethyl)cyclopropyl]methanol Chemical compound OCC1(CO)CC1 YAINYZJQSQEGND-UHFFFAOYSA-N 0.000 description 1
- ZFWQYXYCPDRWRT-UHFFFAOYSA-N [1-(hydroxymethyl)cyclopropyl]methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1(CO)CC1 ZFWQYXYCPDRWRT-UHFFFAOYSA-N 0.000 description 1
- VXAOHVKWMBVJTF-UHFFFAOYSA-N [7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxo-8-[3-(trifluoromethoxy)phenoxy]purin-1-yl]methanesulfonamide Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CS(N)(=O)=O)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 VXAOHVKWMBVJTF-UHFFFAOYSA-N 0.000 description 1
- JETSKDPKURDVNI-UHFFFAOYSA-N [C].[Ca] Chemical compound [C].[Ca] JETSKDPKURDVNI-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- NHADDZMCASKINP-HTRCEHHLSA-N decarboxydihydrocitrinin Natural products C1=C(O)C(C)=C2[C@H](C)[C@@H](C)OCC2=C1O NHADDZMCASKINP-HTRCEHHLSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- VRRJYERADSBBPI-JIZZDEOASA-L dicesium;(2s)-2-aminobutanedioate Chemical compound [Cs+].[Cs+].[O-]C(=O)[C@@H](N)CC([O-])=O VRRJYERADSBBPI-JIZZDEOASA-L 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 206010013461 dissociative amnesia Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- XHQZXHMRBXBPEL-UHFFFAOYSA-N eaton reagent Chemical compound CS(O)(=O)=O.O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 XHQZXHMRBXBPEL-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- JHZPNBKZPAWCJD-UHFFFAOYSA-N ethyl 2-oxocyclopentane-1-carboxylate Chemical compound CCOC(=O)C1CCCC1=O JHZPNBKZPAWCJD-UHFFFAOYSA-N 0.000 description 1
- FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- SKQREYRRCTXZQE-UHFFFAOYSA-N ethyl 5-amino-3-[(4-chlorophenyl)methyl]imidazole-4-carboxylate Chemical compound CCOC(=O)C1=C(N)N=CN1CC1=CC=C(Cl)C=C1 SKQREYRRCTXZQE-UHFFFAOYSA-N 0.000 description 1
- OCCIGHIQVMLYBZ-UHFFFAOYSA-N ethyl 5-methyl-1,2-oxazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C)ON=1 OCCIGHIQVMLYBZ-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SAVROPQJUYSBDD-UHFFFAOYSA-N formyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CO SAVROPQJUYSBDD-UHFFFAOYSA-N 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical group 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- KQEVIFKPZOGBMZ-UHFFFAOYSA-N methyl 3-bromopropanoate Chemical compound COC(=O)CCBr KQEVIFKPZOGBMZ-UHFFFAOYSA-N 0.000 description 1
- XJMIXEAZMCTAGH-UHFFFAOYSA-N methyl 3-oxopentanoate Chemical compound CCC(=O)CC(=O)OC XJMIXEAZMCTAGH-UHFFFAOYSA-N 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 229960003730 methylcellulose (4000 cps) Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- DAMSTKWDQRREMS-GZTJUZNOSA-N n'-[1-[(4-methoxyphenyl)methyl]-3-methyl-2,6-dioxopyrimidin-4-yl]-n,n-dimethylmethanimidamide Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C)C(\N=C\N(C)C)=CC1=O DAMSTKWDQRREMS-GZTJUZNOSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 229940073569 n-methylephedrine Drugs 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VEEMWEXGICUGLW-UHFFFAOYSA-N n-tert-butyl-1-[7-[(4-chlorophenyl)methyl]-3-methyl-2,6-dioxo-8-[3-(trifluoromethoxy)phenoxy]purin-1-yl]methanesulfonamide Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CS(=O)(=O)NC(C)(C)C)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 VEEMWEXGICUGLW-UHFFFAOYSA-N 0.000 description 1
- VZAHIKRUKJZYOE-UHFFFAOYSA-N n-tert-butyl-1-chloromethanesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)CCl VZAHIKRUKJZYOE-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000001354 painful effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- SJMCLWCCNYAWRQ-UHFFFAOYSA-N propane-2-sulfonamide Chemical compound CC(C)S(N)(=O)=O SJMCLWCCNYAWRQ-UHFFFAOYSA-N 0.000 description 1
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000012232 skeletal muscle contraction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940048181 sodium sulfide nonahydrate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- WMDLZMCDBSJMTM-UHFFFAOYSA-M sodium;sulfanide;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[SH-] WMDLZMCDBSJMTM-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003883 substance clean up Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
Abstract
Description
本願は、2013年3月15日出願の米国仮出願番号61/789,724の優先権を主張し、該出願の内容は参照により本出願に組み込まれる。
存在する。イオンチャネルタンパク質の適切な発現および機能は、細胞機能、細胞内情報伝達などの維持に不可欠である。多数の疾患は、膜電位の制御不全または異常カルシウム処理に起因する。細胞での膜電位およびイオン流束を調節することにおいてイオンチャネルが最も重要であることを考慮に入れると、特定のイオンチャネルを促進または阻害できる薬物の同定は、研究手段としておよび可能性のある治療薬としてとても興味深い。
TRPC5のような陽イオンチャネルは、細胞膜を透過するカルシウムおよびナトリウムイオンの流束を調節する。ナトリウムおよびカルシウムの流入は、細胞の脱分極を引き起こす。これは、電位依存性イオンチャネルが活性化に必要とされる閾値に到達する可能性を増加させる。結果として、非選択的陽イオンチャネルの活性化は、電気興奮性を増加させ、電位依存性イベントの頻度を増加させることができる。電位依存性イベントとしては、ニューロン活動電位、心筋活動電位、平滑筋収縮、心筋収縮、および骨格筋収縮が挙げられるが、これらに限定されない。
[式中、
R1は、C1-C6アルキル、C2-C6アルケニルまたはC2-C6アルキニルであり、これらの各々は、1〜4個のR5で適宜置換され;
R2は、C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニル、C2-C6アルキニル、C1-C6ハロアルキル、ハロ、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、C3-C7シクロアルキルオキシ、C6-C10アリール、C6-C10アリールオキシ、C7-C16アリールアルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、-S-、-S-C1-C6アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、ニトロ、またはシアノであり、ここで、該C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニル、C2-C6アルキニル、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、C3-C7シクロアルキルオキシ、C6-C10アリール、C6-C10アリールオキシ、C7-C16アリールアルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、-S-、-S-C1-C6アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、またはアシルの各々は、1〜3個のR6で適宜置換され;
R3は、C1-C6アルキル、C1-C6ヘテロアルキル、C3-C7シクロアルキル、C2-C6アルケニル、C2-C6アルキニル、C2-C6ヒドロキシアルキル、またはC1-C6アルコキシであり、これらの各々は、1〜4個のR7で適宜置換され;
R4は、C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニルまたはC2-C6アルキニルであり、これらの各々は、1〜4個のR8で適宜置換され;
R5、R6、R7、およびR8は、各々独立してC1-C6アルキル、C1-C6ヘテロアルキル、ハロ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、シアノ、ニトロ、アミド、C1-C6アルキルアミド、C2-C12ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6アルキル、C3-C7シクロアルキル、C6-C10アリール、ヘテロシクロアルキル、またはヘテロアリールであり、ここで、該C1-C6アルキル、C1-C6ヘテロアルキル、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、アミド、C1-C6アルキルアミド、C2-C12ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6アルキル、C3-C7シクロアルキル、C6-C10アリール、ヘテロシクロアルキル、またはヘテロアリールの各々は、1〜3個のR9で適宜置換され;そして
各R9は、独立してC1-C6アルキル、C1-C6ヘテロアルキル、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヘテロシクロアルキル、C6-C10アリール、ヘテロアリール、C4-C10シクロアルキルアルキル、ヘテロシクロアルキル-C1-C6アルキル、C7-C16アリールアルキル、ヘテロアリール-C1-C6アルキル、ハロ、ヒドロキシル、C1-C6アルコキシ、C6-C10アリールオキシ、C7-C16アリールアルコキシ、C2-C8アルコキシアルコキシル、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、C1-C6アルキル-アミノ-C1-C6アルキル、C1-C6アルキル-アミノ-C2-C12ジアルキル、-S-、-S-C1-C6アルキル、-S(O)2-C1-C6アルキル、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、-C(O)-C6-C10アリール、-NHC(O)-C6-C10アリール、-C(O)NH-C6-C10アリール、-C(O)OH、-C(O)O-C1-C6アルキル、-C(O)-C1-C6アルキルアシル、ニトロ、またはシアノである]
で示される化合物またはその医薬的に許容される塩を対象に投与しその結果対象を処置すること含む。
[式中、
R1は、C1-C6アルキル、C2-C6アルケニルまたはC2-C6アルキニルであり、これらの各々は、1〜4個のR5で適宜置換され;
R2は、C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニル、C2-C6アルキニル、C1-C6ハロアルキル、ハロ、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、C3-C7シクロアルキルオキシ、C6-C10アリール、C6-C10アリールオキシ、C7-C16アリールアルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、-S-、-S-C1-C6アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、ニトロ、またはシアノであり、ここで、C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニル、C2-C6アルキニル、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、C3-C7シクロアルキルオキシ、C6-C10アリール、C6-C10アリールオキシ、C7-C16アリールアルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、-S-、-S-C1-C6アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、またはアシルの各々は、1〜3個のR6で適宜置換され;
R3は、C2-C6ヒドロキシアルキルまたはC1-C6ヘテロアルキルであり;
R4は、C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニルまたはC2-C6アルキニルであり、これらの各々は、1〜4個のR8で適宜置換され;
R5、R6、およびR8は、各々独立してC1-C6アルキル、C1-C6ヘテロアルキル、ハロ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、シアノ、ニトロ、アミド、C1-C6アルキルアミド、C2-C12ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6アルキル、C3-C7シクロアルキル、C6-C10アリール、ヘテロシクロアルキル、またはヘテロアリールであり、該C1-C6アルキル、C1-C6ヘテロアルキル、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、アミド、C1-C6アルキルアミド、C2-C12ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6アルキル、C3-C7シクロアルキル、C6-C10アリール、ヘテロシクロアルキル、またはヘテロアリールの各々は、1〜3個のR9で適宜置換され;そして
各R9は、独立してC1-C6アルキル、C1-C6ヘテロアルキル、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヘテロシクロアルキル、C6-C10アリール、ヘテロアリール、C4-C10シクロアルキルアルキル、ヘテロシクロアルキル-C1-C6アルキル、C7-C16アリールアルキル、ヘテロアリール-C1-C6アルキル、ハロ、ヒドロキシル、C1-C6アルコキシ、C6-C10アリールオキシ、C7-C16アリールアルコキシ、C2-C8アルコキシアルコキシル、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、C1-C6アルキル-アミノ-C1-C6アルキル、C1-C6アルキル-アミノ-C2-C12ジアルキル、-S-、-S-C1-C6アルキル、-S(O)2-C1-C6アルキル、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、-C(O)-C6-C10アリール、-NHC(O)-C6-C10アリール、-C(O)NH-C6-C10アリール、-C(O)OH、-C(O)O-C1-C6アルキル、-C(O)-C1-C6アルキルアシル、ニトロ、またはシアノである]
で示される化合物またはその医薬的に許容される塩を提供する。
[式中、
環Aは、フェニル、ピリジル、チアゾリル、ピリミジニル、またはオキサゾリルであり;
R2は、C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニル、C2-C6アルキニル、C1-C6ハロアルキル、ハロ、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、C3-C7シクロアルキルオキシ、C6-C10アリール、C6-C10アリールオキシ、C7-C16アリールアルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、-S-、-S-C1-C6アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、ニトロ、またはシアノであり、ここで、C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニル、C2-C6アルキニル、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、C3-C7シクロアルキルオキシ、C6-C10アリール、C6-C10アリールオキシ、C7-C16アリールアルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、-S-、-S-C1-C6アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、またはアシルの各々は、1〜3個のR6で適宜置換され;
R3は、C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニル、C2-C6アルキニル、C2-C6ヒドロキシアルキル、またはC1-C6アルコキシであり、これらの各々は、1〜4個のR7で適宜置換され;
R4は、C1-C6アルキル、C1-C6ヘテロアルキル、C2-C6アルケニルまたはC2-C6アルキニルであり、これらの各々は、1〜4個のR8で適宜置換され;
R6、R7、およびR8は、各々独立してC1-C6アルキル、C1-C6ヘテロアルキル、ハロ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、シアノ、ニトロ、アミド、C1-C6アルキルアミド、C2-C12ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6アルキル、C3-C7シクロアルキル、C6-C10アリール、ヘテロシクロアルキル、またはヘテロアリールであり、ここで、該C1-C6アルキル、C1-C6ヘテロアルキル、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヒドロキシル、C1-C6アルコキシ、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、アミド、C1-C6アルキルアミド、C2-C12ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6アルキル、C3-C7シクロアルキル、C6-C10アリール、ヘテロシクロアルキル、またはヘテロアリールの各々は、1〜3個のR9で適宜置換され;
各R9は、独立してC1-C6アルキル、C1-C6ヘテロアルキル、C1-C6ハロアルキル、C1-C6ハロアルコキシ、ヘテロシクロアルキル、C6-C10アリール、ヘテロアリール、C4-C10シクロアルキルアルキル、ヘテロシクロアルキル-C1-C6アルキル、C7-C16アリールアルキル、ヘテロアリール-C1-C6アルキル、ハロ、ヒドロキシル、C1-C6アルコキシ、C6-C10アリールオキシ、C7-C16アリールアルコキシ、C2-C8アルコキシアルコキシル、アミノ、C1-C6アルキルアミノ、C2-C12ジアルキルアミノ、C1-C6アルキル-アミノ-C1-C6アルキル、C1-C6アルキル-アミノ-C2-C12ジアルキル、-S-、-S-C1-C6アルキル、-S(O)2-C1-C6アルキル、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、-C(O)-C6-C10アリール、-NHC(O)-C6-C10アリール、-C(O)NH-C6-C10アリール、-C(O)OH、-C(O)O-C1-C6アルキル、-C(O)-C1-C6アルキルアシル、ニトロ、またはシアノであり;
各Raは、C1-C6アルキル、C1-C6ハロアルキル、ハロであり;
nは、1または2であり;そして
mは、1、2、または3である]
で示される化合物またはその医薬的に許容される塩を提供する。
[式中、
R2は、1〜3個のR6で置換された、C1-C6アルコキシまたはC6-C10アリールオキシであり;
R3は、C1-C6ヘテロアルキルまたはC2-C6ヒドロキシアルキルであり;
R4は、C1-C6アルキルであり;
R6は、独立してC1-C6アルキル、ハロ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、またはC1-C6アルコキシであり;
各Raは、C1-C6アルキル、C1-C6ハロアルキル、ハロであり;
nは、1または2であり;そして
mは、1、2、または3である]
で示される化合物またはその医薬的に許容される塩を提供する。
本明細書の様々な箇所において、本願に記載の化合物の置換基は、グループまたは範囲をもって開示される。具体的には、本発明は、そうしたグループおよび範囲の構成要素の各々およびすべてのサブコンビネーションを含むことを意図する。例えば、用語「C1-6アルキル」は、具体的にメチル、エチル、C3アルキル、C4アルキル、C5アルキル、およびC6アルキルをそれぞれ開示することを意図する。
-NRa-C(O)-NRa-SO2-を意味し、ここでRaは、HまたはC1-C6アルキルである。
ある特定の実施態様において、本発明は、インビトロまたはインビボにおいてTRPC5チャネルの機能を拮抗するための方法および組成物を提供する。典型的な機能としては、TRPC5-介在性電流が挙げられるが、これに限定されない。ある特定の実施態様において、本発明は、本願に記載の化合物を投与することにより疾患、障害または病態を処置する方法を提供する。他の実施態様において、式(I)で示される化合物は、タンパク質の発現レベルおよび/または活性を選択的に阻害する。言い換えると、ある特定の実施態様において、本願に記載の化合物は、1以上の他のイオンチャネルの活性と比較してTRPC5タンパク質の活性を選択的に阻害する。
ある特定の実施態様において、本願に記載の化合物は、不安および恐怖に関連した障害を防止するまたは処置するために用いられ得る(例えば、Riccio et al. (2009) Cell 137:761-72参照)。そうした障害の例としては、外傷後ストレス障害、パニック障害、広場恐怖症、社会恐怖症、全般性不安障害、パニック障害、社会不安障害、強迫性障害、および分離不安が挙げられる。
本願に記載の化合物はまた、パーキンソン病、癲癇、記憶障害、卒中、発作、および気分障害の処置に有用である。気分障害としては、うつ病(例えば、大うつ、精神的うつ病、気分変調症、および産後うつ病)および双極性障害(例えば、双極性I、双極性II、および気分循環症)が挙げられる。記憶障害は、任意の記憶欠如に関連する病態であり、アルツハイマー病、健忘症、失語症、アテローム性動脈硬化症、脳傷害または障害、脳腫瘍、慢性疲労症候群、クロイツフェルト・ヤコブ病、解離性健忘症、うつ病、徘徊性健忘症、ハンチントン病、学習障害、睡眠障害、多重人格障害、痛み、外傷後ストレス障害、統合失調症、スポーツでの怪我、卒中、およびウェルニッケ・コルサコフ症候群により生じ得る。
ある特定の実施態様において、本願に記載の化合物は、痛みを処置するまたは軽減するために用いられる。式(I)で示される化合物を用いて処置され得る痛みの典型的な分類としては、侵害受容性疼痛、炎症性疼痛、および神経障害性疼痛が挙げられるが、これらに限定されない。該疼痛は、慢性または急性であり得る。
神経変性疾患および障害としては、アルツハイマー病(AD)、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症(ALS)、および心的外傷または他の加齢を含む損傷によって生じる他の脳障害が挙げられるが、これらに限定されない。
様々な起源の興奮毒性は、発作を生じる。通常の過剰なニューロン発火は、発作活動を生じさせる。関連する神経集団の過剰興奮性を減少させる化合物は、発作活動を減少さることについて大きな潜在的可能性を有する。TRPC5を阻害する本願に記載の化合物は、過剰興奮性を減少させ得て、その結果発作活動を減少させる。
TRPC5はまた、腎臓の糸球体足細胞(podocyte)に発現する。糸球体足細胞においてTRPC5およびTRPC6によるアクチン動態および細胞の拮抗的制御があると提示されている(Tian et al., (2010) Science Signaling)。したがって、TRPC5を阻害することは、傷害に対する糸球体足細胞の反応に影響を与え得る。
本発明は、インビトロおよびインビボにおける使用のための本願に記載の化合物を提供する。本発明はまた、TRPC5活性を阻害する式(I)で示される化合物を含む組成物および医薬組成物を提供する。ある特定の実施態様において、本願に記載の化合物は、選択的である。言い換えると、ある特定の実施態様において、本願に記載の化合物は、TRPC5活性を他のイオンチャネルの活性を越えて優先的に阻害する。ある特定の実施態様において、式(I)で示される化合物は、TRPC5活性をTRPV1、TRPV2、TRPV3、TRPV4、TRPC3、TRPC6、TRPC7、TRPA1、および/またはTRPM8活性を越えて優先的に阻害する。例えば、ある特定の実施態様においては、式(I)で示される化合物は、TRPC5の活性を阻害し、また1以上のTRPC4、TRPV1、TRPV2、TRPV3、TRPV4、TRPC3、TRPC6、TRPC7、TRPA1、およびTRPM8の活性を阻害する。
本願に記載の化合物は単独で投与されることが可能である一方、医薬製剤として化合物を投与することが好ましく、ここで化合物は、1以上の医薬的に許容される賦形剤または担体と組み合わされる。本願に記載の化合物は、投与するためにヒトまたは動物用薬の用途に任意の適当な方法により製剤化されてもよい。ある特定の実施態様において、本願に記載の化合物は、プロドラッグでもよく、例えば、生理学的環境で活性化合物に変換されることが可能であるものである。
または医薬的に許容される担体と組み合わせて本願に記載の化合物の例えば0.1〜99.5%(より好ましくは、0.5〜90%)を含む医薬組成物として与えられることができる。
本願に記載の医薬組成物中における本願に記載の化合物の実際の用量レベルは、特定の患者、組成物、および投与様式に対して患者に毒性なく所望の治療的反応を達成するのに効果的である有効成分の量を確立するために変えることができる。
TRPC5機能を拮抗する本願に記載の化合物は、任意の前述した傷害、疾患、障害、または病態の予防及び処置において有用であり得る。本願に記載の化合物の活性のインビトロアッセイに加えて、その有効性は1以上の動物モデルで容易に試験され得る。例として、多数のよく知られた動物モデルが存在する。1以上の適切な動物モデル(例えば、特定の兆候を踏まえて適切である)を選択できる。
方法A:パッチクランプ実験
パッチクランプ実験は、上記の細胞株におけるTRPC5チャネル通る電流の測定を可能にする。通常の全細胞パッチクランプ記録において、ガラス電極を単一細胞に接触させ、高抵抗(ギガオーム)シールを細胞膜に設置する。その後膜を断裂し、全細胞配置を得て、細胞膜電位のコントロールおよび電極に接続した増幅器を用いた膜を通る電流の測定を可能にし、そしてピペット溶液での細胞質の置換を生じる。潅流システムは、電流のブロッカーおよびアクティベーターの添加を含む細胞外溶液のコントロールを可能にする。電流を、ピペット(細胞内)溶液中に1.4 μMの遊離 Ca2+、および細胞外溶液中に80 μMのLaCl3を含ませることにより活性化できる。
ハイスループットアッセイは、TRPC5チャネルを誘導発現した細胞におけるチャンネル活性化後、細胞内Ca2+濃度([Ca2+]i)の上昇の検出によって決めた。Ca2+増加を細胞に入れた蛍光Ca2+指示薬を用いて測定し、その後TRPC5チャネルの活性化後、[Ca2+]i Ca2+流入を示した。[Ca2+]i上昇を阻害した化合物を、さらに調べるための当たりと判断した。
一般的な手順
すべての試薬を、市販業者から購入し、他に明記しない限りさらに精製することなく用いた。THFを、連続的に還流し、新しくナトリウムおよびベンゾフェノンから窒素下蒸留し、DCMを連続的に還流し、新しくCaH2から窒素下蒸留した。
BPO 過酸化ベンゾイル
CDI カルボニルジイミダゾール
クロマトグラフィー シリカゲルを用いた化合物精製
濃縮(または減圧濃縮) ロータリーエバポレーション装置を用いた溶媒除去
DCM ジクロロメタン
DBU 1,8-ジアザビシクロ[5.4.0]ウンデカ-7-エン
デス・マーチン(またはデス・マーチン ペルヨージナン) 1,1,1-トリアセトキシ-1,1-ジヒドロ-1,2-ベンゾヨードキソール-3(1H)-オン
希HCl 1 N塩酸
DMF N,N-ジメチルホルムアミド
DMAP 4-ジメチルアミノピリジン
乾燥 硫酸ナトリウムのような無機乾燥剤の使用を含意する有機溶液から残留水の除去
真空乾燥(または真空下で乾燥) 真空ポンプを用いた溶媒除去
DMSO ジメチルスルホキシド
イートン試薬 7.7 重量%のメタンスルホン酸中の五酸化リン
EDCI 1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド
エバポレート ロータリーエバポレーション装置を用いた溶媒除去
h 時間
HMDS ヘキサメチルジシラザン
LAH 水素化アルミニウムリチウム
MCPBA 3-クロロペルオキシ安息香酸
min 分
n-BuLi n-ブチルリチウム
NBS N-ブロモスクシンイミド
NCS N-クロロスクシンイミド
NMP N-メチルピロリジノン
オキソン ペルオキソ一硫酸カリウム
Pd/C パラジウム炭素
Pd-dppf 1,1'-ビス(ジフェニルホスフィノ)フェロセン-パラジウム(II)ジクロリド-ジクロロメタン複合体
PMB 4-メトキシベンジル
PPTS p-トルエンスルホン酸ピリジニウム
分取TLC 分取薄層クロマトグラフィー
SEM (トリメチルシリル)エトキシメチル
TBAI ヨウ化テトラブチルアンモニウム
TBAF フッ化テトラブチルアンモニウム
TBAH 水酸化テトラブチルアンモニウム
TEA トリエチルアミン
TFA トリフルオロ酢酸
THF テトラヒドラフラン
tlc 薄層シリカゲルクロマトグラフィー
X-phos 2-(ジシクロヘキシルホスフィノ)-2',4',6'-トリイソプロピルビフェニル
中間体1 2-(2-(2-クロロエトキシ)エトキシ)テトラヒドロ-2H-ピラン
実施例1 7-(4-クロロベンジル)-3-メチル-8-(3-(トリフルオロメチル)フェノキシ)-1H-プリン-2,6(3H,7H)-ジオン
ノート:C5-0249-047
実施例373に記載の方法を用いた。白色固体, 0.13 g, 63%収率:LCMS保持時間 = 3.970分, 95%純度, LCMS MH+ 447. 1H NMR (DMSO-d6) δ 7.34 (dd, 4H, J = 8 Hzおよび44 Hz), 5.21 (s, 2H), 4.42 (brd s, 1H), 4.31 (d, 2H, J = 4 Hz), 3.89 (t, 3H, J = 8 Hz), 3.41 (t, 2H, J = 8 Hz), 3.35 (s, 3H), 2.23-2.35 (m, 2H), 1.62-1.72 (m, 4H), 1.44-1.59 (m, 4H), 1.16-1.28 (m, 2H).
強制水泳試験(FST)は、最も広く用いられる抗うつ作用活性のインビボモデルの1つである。この試験で観察される不動性は、すべての主要な分類の抗うつ剤により改善させることができるうつ病性ストレス惹起行動を意味する(Porsolt et al., Arch Int Pharmacodyn Ther. 229(2):327-36, 1977; Porsolt et al., Nature 266: 730 - 732, 1977) (Lucki, et al., Psychopharmacology (Berl). 155(3):315-22, 2001)。要するに、雄性CD-1マウス(7週齢、Charles RiverLabs)群に0.5%メチルセルロース(MC)または様々な濃度の本願に記載の化合物を経口投与した。陽性コントロール、イミプラミン、を腹腔内注射(IP)により20 mg/kgで投与した。投与直後に、マウスをホームケージに戻した。メチルセルロース投与または本願に記載の化合物投与の60分後、およびイミプラミン投与の45分後、マウスをポリカーボネートシリンダー(直径22.2 cm、高さ25.3 cm;Fisher Scientific、ピッツバーグ、ペンシルベニア州)にそれぞれ入れ、15 cmの水で満たし、24±1℃の温度で維持した。以下の実施例において、本願に記載の化合物を投与した後、不動性または水泳行動を6分間記録した。6分間の水泳セッション後、マウスをタオルで乾燥し、ホームケージに戻した。
マウスに10 mL/kgの0.5%メチルセルロース(MC)を経口で、または0.1、0.3もしくは1 mg/kgの化合物 31を経口で、チャンバーに入れる60分前に投与した。イミプラミンを腹腔内注射により20 mg/kgで試験の45分前に投与した。
マウスに10 mL/kgの0.5%メチルセルロース(MC)を経口で、または0.3、1もしくは3 mg/kgの化合物 260を、チャンバーに入れる60分前に投与した。陽性コントロール、イミプラミンを腹腔内注射により20 mg/kgで試験の45分前に投与した。
マウスに10 mL/kgの0.5%メチルセルロース(MC)を、または3、10、30もしくは100 mg/kgの用量で化合物 587を、試験の1時間前に経口投与により与えた;あるいはそれらに20 mg/kgのイミプラミンを腹腔内注射により試験の45分前に投与により与えた。
マウスに10 mL/kgの0.5%メチルセルロース(MC)を、または3、10もしくは30 mg/kgの化合物 458を、試験の1時間前に経口投与により与えた;あるいはそれらに20 mg/kgのイミプラミンを腹腔内注射により試験の45分前に投与により与えた。化合物 458は、抗不安作用を示すマウスが不動であった時間を減少させた。
マウスに10 mL/kgの0.5%メチルセルロース(MC)をまたは0.3、1、もしくは3 mg/kgの化合物 556を、試験の1時間前に経口投与により与えた;あるいはそれらに20 mg/kgのイミプラミンを腹腔内注射により試験の45分前に投与により与えた。
Steruらにより説明された尾懸垂試験(L. Steru, R. Chermat, B. Thierry, and P. Simon, Psychopharmacology 85(3): 367-370, 1985)が、強制水泳試験とともに最も広く用いられるうつ病の動物モデルの1つとなっている(Cryan JF, Mombereau C, Vassout A., Neurosci. Biobehav. Rev. 29(4-5): 571-625, 2005)。
齧歯動物は、有害な物質を埋めるため敷料を用いることを示しているが、しかしながらそれらはまた、ラット用固形飼料およびガラス玉などの無害な対象を埋める。この行動は、セロトニン吸収阻害剤の投与により防止される。それは、強迫神経障害のヒトにおいて効果的であると見出されているセロトニン吸収阻害剤により減少できるため、ガラス玉埋めは強迫行動であると提示されている(Njung'e, K., et al. Pharmacol. Biochem. Behav. 38(1): 63-7, 1991)。
マウスに10 mL/kgの0.5%メチルセルロース(MC)を経口で、または0.1、0.3もしくは1 mg/kgの化合物 31を経口で、試験の60分前に投与した。陽性コントロール、10 mg/kgのジメリジン、を腹腔内注射により試験の45分前に投与した。0.3および1 mg/kgにおいて、化合物 31は、経口投与したコントロールと比較して埋められたガラス玉の数を減少させることができた。
マウスに10 mL/kgの0.5%メチルセルロース(MC)を経口で、または1、3もしくは10 mg/kgの化合物 260を経口で、試験の60分前に投与した。陽性コントロール、10 mg/kgのジメリジン、を腹腔内注射により試験の45分前に投与した。
マウスに10 mL/kgの0.5%メチルセルロース(MC)を経口で、または3、10もしくは30 mg/kgの化合物 587を経口で、試験の60分前に投与した。陽性コントロール、10 mg/kgのジメリジン、を腹腔内注射により試験の45分前に投与した。
マウスに10 mL/kgの0.5%メチルセルロース(MC)を経口で、または3、10、30もしくは60 mg/kgの化合物 458を経口で、試験の15分前に投与した。陽性コントロール、10 mg/kgのジメリジン、を腹腔内注射により試験の45分前に投与した。
30年以上の間、Vogel型コンフリクトテストは、齧歯動物において不安を取り除く薬物の能力を測定するインビボ動物モデルとして用いられている(Millan MJ, Brocco M, Eur J Pharmacol. 463(1-3): 67-96, 2003)。要するに、水を48時間などのある特定の期間動物に控えさせる。その期間経過後、動物に水を自由に摂取できるようにするが、定義された数なめた後生じる間欠期に弱い電気ショック、例えば20回なめた毎にショック、を動物は水源から受ける。未処置ラットは、飲水を拒否することにより顕在化された回避行動を生じる。ラットにおけるこの回避型行動または内面葛藤行動は、ヒトにおける回避葛藤に類似する(Cryan JF, Sweeney FF, British Journal of Pharmacology, 2011; 164: 1129-1161)。
高架十字迷路試験は、抗不安活性を評価するためのインビボモデルである。該試験は、壁なしまたは壁あり走路に暴露された齧歯動物が壁あり走路でより長い時間を過ごすというMontgomeryによる観察(Montgomery, KC., T Comp Physiol Psychol. 48: 254-260, 1958)に基づいており、これは接近−回避葛藤として特徴づけられる。これに基づいて、は、HandleyおよびMithani(Handley SL, Mithani S., Naunyn-Schmiedeberg's Arch Pharmacol. 327: 1-5, 1984)は、2個の壁ありおよび2個の壁なし走路を有する形の高架迷路を用いた適応を考案した。高架十字迷路試験において、動機付け葛藤を規定し、ここで、新しい環境を探索する動物の生まれ持った傾向が、壁なし走路を恐れることにより妨害される。抗不安操作は、壁なし領域を避ける活力を減少させ、したがって壁なし走路への侵入および滞在時間を増加させる。さらに、Riccioらは、C57/BL6 TrpC5ノックアウトマウスの使用により、TrpC5の活性化は高架十字迷路における恐怖反応の増加を生じる(Riccio A et al., Cell 137: 761-772, 2009)が、葛藤回避の新規な抑制摂食試験においては生じないことを示した。
上記の方法を用いて、化合物 31で処置したマウスで見られた作用の持続性を試験した。マウスに、試験の30分前に0.5%メチルセルロース(MC)の経口投与;または試験の30分、60分、もしくは120分前に1 mg/kgの用量で化合物 31の経口投与のいずれかをした。ビデオを、処置に対して盲目にされた記録員により手作業で壁なし走路侵入数について記録した。化合物 31で処置したマウスは、MCで処置したマウスより多くおよびより長く迷路の壁なし走路領域に滞在し、化合物 31で見られた効果は少なくとも2時間の持続性を有することを示した。より長い持続性は試験しなかった。
Wistar-Kyotoラットを高架十字迷路アッセイで用い、1 mg/kg用量のミダゾラムおよび0.5%メチルセルロースをそれぞれ陽性および陰性コントロールとして、ならびに0.3、1、3および10 mg/kgの用量で化合物 260を用いた。結果は、ラットは迷路の壁なし部分で有意な時間滞在しなかった(図3Aおよび3B);しかしながら、それらは、壁あり走路部分においてビヒクルまたはミダゾラムを投与したラットより活動的である(図3C)ことを示した。化合物 260を投与したとき(図3D)、より長い距離(センチメーター単位で測定)を進んだラットは増加した。
ラットが本願に記載の化合物の刺激効果に対して反応しないことを保証するため、化合物 260を試験した。この実施例において、皮下投与により0.5%メチルセルロース(MC)(ビヒクル)と5 mg/kg用量でフェンシクリジン(PCP)(図4A)を、または様々な用量の化合物 260(図4B)をNMRIマウスにおいて試験した。PCPで処置したマウスは、メチルセルロースと比較して有意に高いレベルの運動活性化を有し、顕著な刺激効果を示したが、一方複数の用量での化合物 260は、コントロールと比べまったく刺激効果の違いを示さなかった。この実施例は、高架十字迷路における化合物 260処置ラットの探索が増加したことは、化合物 260のPCP様効果によるものではないことを実証する。
個々の公報または特許が具体的におよび個々に参照により組み込まれると示されているように、本明細書で言及したすべての公報および特許は、そのまま参照により本明細書に組み込まれる。
当業者は、本明細書に記載された発明の具体的な実施態様に対する多くの均等物を、単なる通常の実験を用いて認識または確認できるであろう。そうした均等物を以下の請求の範囲に含包することを意図する。
Claims (35)
- 対象においてTRPC5介在障害を処置する方法であって、式I:
式I
[式中
R1は、C1-C6 アルキル、C2-C6 アルケニルまたはC2-C6 アルキニルであり、これらの各々は、1〜4個のR5で適宜置換され;
R2は、C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニル、C2-C6 アルキニル、C1-C6 ハロアルキル、ハロ、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、C3-C7 シクロアルキルオキシ、C6-C10 アリール、C6-C10 アリールオキシ、C7-C16 アリールアルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、-S-、-S-C1-C6 アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、ニトロ、またはシアノであり、ここで、該C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニル、C2-C6 アルキニル、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、C3-C7 シクロアルキルオキシ、C6-C10 アリール、C6-C10 アリールオキシ、C7-C16 アリールアルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、-S-、-S-C1-C6 アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、またはアシルの各々は、1〜3個のR6で適宜置換され;
R3は、C1-C6 アルキル、C1-C6 ヘテロアルキル、C3-C7 シクロアルキル、C2-C6 アルケニル、C2-C6 アルキニル、C2-C6 ヒドロキシアルキル、またはC1-C6 アルコキシであり、これらの各々は、1〜4個のR7で適宜置換され;
R4は、C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニルまたはC2-C6 アルキニルであり、これらの各々は、1〜4個のR8で適宜置換され;
R5、R6、R7、およびR8 は、各々独立してC1-C6 アルキル、C1-C6 ヘテロアルキル、ハロ、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、シアノ、ニトロ、アミド、C1-C6 アルキルアミド、C2-C12 ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6 アルキル、C3-C7 シクロアルキル、C6-C10 アリール、ヘテロシクロアルキル、またはヘテロアリールであり、ここで、該C1-C6 アルキル、C1-C6 ヘテロアルキル、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、アミド、C1-C6 アルキルアミド、C2-C12 ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6 アルキル、C3-C7 シクロアルキル、C6-C10 アリール、ヘテロシクロアルキル、またはヘテロアリールの各々は、1〜3個のR9で適宜置換され;そして
各R9は、独立してC1-C6 アルキル、C1-C6 ヘテロアルキル、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヘテロシクロアルキル、C6-C10 アリール、ヘテロアリール、C4-C10 シクロアルキルアルキル、ヘテロシクロアルキル-C1-C6 アルキル、C7-C16 アリールアルキル、ヘテロアリール-C1-C6 アルキル、ハロ、ヒドロキシル、C1-C6 アルコキシ、C6-C10 アリールオキシ、C7-C16 アリールアルコキシ、C2-C8 アルコキシアルコキシル、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、C1-C6 アルキル-アミノ-C1-C6 アルキル、C1-C6 アルキル-アミノ-C2-C12 ジアルキル、-S-、-S-C1-C6 アルキル、-S(O)2-C1-C6 アルキル、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、-C(O)-C6-C10 アリール、-NHC(O)-C6-C10 アリール、-C(O)NH-C6-C10 アリール、-C(O)OH、-C(O)O-C1-C6 アルキル、-C(O)-C1-C6 アルキルアシル、ニトロ、またはシアノである]
で示される化合物、またはその医薬的に許容される塩を対象に投与しその結果対象を処置することを含む、該方法。 - TRPC5介在障害が、神経精神障害、神経変性障害、腎症、および発作性障害からなる群より選択される、請求項1記載の方法。
- R1が、C1-C6 アルキルである請求項1記載の方法、またはその医薬的に許容される塩。
- R1が、C1-C6 アルキルであり、R5が、独立してC6-C10 アリールまたはヘテロアリールである、請求項1記載の方法、またはその医薬的に許容される塩。
- R2が、C6-C10 アリール、C6-C10 アリールオキシまたはヘテロアリールオキシである、請求項1記載の方法、またはその医薬的に許容される塩。
- R2が、C6-C10 アリールオキシである、請求項1記載の方法、またはその医薬的に許容される塩。
- R2が、C1-C6 アルコキシである、請求項1記載の方法、またはその医薬的に許容される塩。
- R2が、C1-C6 アルキルである、請求項1記載の方法、またはその医薬的に許容される塩。
- R2が、C1-C6 アルキルアミノである、請求項1記載の方法、またはその医薬的に許容される塩。
- R2が、-S(O)-または-S(O)2-である、請求項1記載の方法、またはその医薬的に許容される塩。
- R3が、C1-C6 アルキル、C2-C6 ヒドロキシアルキル、またはC1-C6 アルコキシである、請求項1記載の方法、またはその医薬的に許容される塩。
- R3が、ヒドロキシプロピルである、請求項1記載の方法、またはその医薬的に許容される塩。
- R4が、C1-C6 アルキルである、請求項1記載の方法、またはその医薬的に許容される塩。
- R5が、独立してC6-C10 アリール、ヘテロアリール、C3-C7 シクロアルキル、またはヘテロシクロアルキルである、請求項1記載の方法、またはその医薬的に許容される塩。
- R5が、フェニル、ピリジル、チアゾリル、ピリミジニル、またはオキサゾリルである、請求項1記載の方法、またはその医薬的に許容される塩。
- R5が、フェニルである、請求項1記載の方法、またはその医薬的に許容される塩。
- R5が、ピリジルである、請求項1記載の方法、またはその医薬的に許容される塩。
- R5が、チアゾリルである、請求項1記載の方法、またはその医薬的に許容される塩。
- R9が、独立してC1-C6 アルキル、C1-C6 アルコキシ、ハロ、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、またはヘテロシクロアルキルである、請求項1記載の方法、またはその医薬的に許容される塩。
- R2が、C6-C10 アリールまたはC6-C10 アリールオキシであり、R6が、独立してC1-C6 アルキル、C1-C6 ハロアルキル、またはC1-C6ハロアルコキシである、請求項1記載の方法、またはその医薬的に許容される塩。
- R2が、C6-C10 アリールオキシであり、R6が、独立してC1-C6 ハロアルキル、またはC1-C6ハロアルコキシである、請求項1記載の方法、またはその医薬的に許容される塩。
- R2が、C6-C10 アリールオキシであり、R6が、-CF3または-OCF3である、請求項1記載の方法、またはその医薬的に許容される塩。
- 式I(a):
式I(a)
[式中
R1は、C1-C6 アルキル、C2-C6 アルケニルまたはC2-C6 アルキニルであり、これらの各々は、1〜4個のR5で適宜置換され;
R2は、C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニル、C2-C6 アルキニル、C1-C6 ハロアルキル、ハロ、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、C3-C7 シクロアルキルオキシ、C6-C10 アリール、C6-C10 アリールオキシ、C7-C16 アリールアルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、-S-、-S-C1-C6 アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、ニトロ、またはシアノであり、ここで、C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニル、C2-C6 アルキニル、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、C3-C7 シクロアルキルオキシ、C6-C10 アリール、C6-C10 アリールオキシ、C7-C16 アリールアルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、-S-、-S-C1-C6 アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、またはアシルの各々は、1〜3個のR6で適宜置換され;
R3は、C2-C6 ヒドロキシアルキルまたはC1-C6 ヘテロアルキルであり;
R4は、C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニルまたはC2-C6 アルキニルであり、これらの各々は、1〜4個のR8で適宜置換され;
R5、R6、およびR8は、各々独立してC1-C6 アルキル、C1-C6 ヘテロアルキル、ハロ、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、シアノ、ニトロ、アミド、C1-C6 アルキルアミド、C2-C12 ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6 アルキル、C3-C7 シクロアルキル、C6-C10 アリール、ヘテロシクロアルキル、またはヘテロアリールであり、該C1-C6 アルキル、C1-C6 ヘテロアルキル、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、アミド、C1-C6 アルキルアミド、C2-C12 ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6 アルキル、C3-C7 シクロアルキル、C6-C10 アリール、ヘテロシクロアルキル、またはヘテロアリールの各々は、1〜3個のR9で適宜置換され;そして
各R9は、独立してC1-C6 アルキル、C1-C6 ヘテロアルキル、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヘテロシクロアルキル、C6-C10 アリール、ヘテロアリール、C4-C10 シクロアルキルアルキル、ヘテロシクロアルキル-C1-C6 アルキル、C7-C16 アリールアルキル、ヘテロアリール-C1-C6 アルキル、ハロ、ヒドロキシル、C1-C6 アルコキシ、C6-C10 アリールオキシ、C7-C16 アリールアルコキシ、C2-C8 アルコキシアルコキシル、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、C1-C6 アルキル-アミノ-C1-C6 アルキル、C1-C6 アルキル-アミノ-C2-C12 ジアルキル、-S-、-S-C1-C6 アルキル、-S(O)2-C1-C6 アルキル、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、-C(O)-C6-C10 アリール、-NHC(O)-C6-C10 アリール、-C(O)NH-C6-C10 アリール、-C(O)OH、-C(O)O-C1-C6 アルキル、-C(O)-C1-C6 アルキルアシル、ニトロ、またはシアノである]
で示される化合物、またはその医薬的に許容される塩。 - R1が、C1-C6 アルキルであり、R5が、フェニル、ピリジル、チアゾリル、ピリミジニル、またはオキサゾリルである、請求項23記載の化合物、またはその医薬的に許容される塩。
- R2が、C6-C10 アリールまたはC6-C10 アリールオキシであり、R6が、独立してC1-C6 アルキル、C1-C6 ハロアルキル、C1-C6またはハロアルコキシである、請求項23記載の化合物、またはその医薬的に許容される塩。
- R3が、C2-C6 ヒドロキシアルキルである、請求項23記載の化合物、またはその医薬的に許容される塩。
- 式II:
式II
[式中
環Aは、フェニル、チアゾリル、ピリミジニル、またはオキサゾリルであり;
R2は、C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニル、C2-C6 アルキニル、C1-C6 ハロアルキル、ハロ、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、C3-C7 シクロアルキルオキシ、C6-C10 アリール、C6-C10 アリールオキシ、C7-C16 アリールアルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、-S-、-S-C1-C6 アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、ニトロ、またはシアノであり、ここで、C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニル、C2-C6 アルキニル、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、C3-C7 シクロアルキルオキシ、C6-C10 アリール、C6-C10 アリールオキシ、C7-C16 アリールアルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、-S-、-S-C1-C6 アルキル、-S(O)-、-S(O)2-、ヘテロシクロアルキル、ヘテロアリール、ヘテロアリールオキシ、スルホンアミジル、アミド、ウレア、スルホニルウレア、またはアシルの各々は、1〜3個のR6で適宜置換され;
R3は、C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニル、C2-C6 アルキニル、C2-C6 ヒドロキシアルキル、またはC1-C6 アルコキシであり、これらの各々は、1〜4個のR7で適宜置換され;
R4は、C1-C6 アルキル、C1-C6 ヘテロアルキル、C2-C6 アルケニルまたはC2-C6 アルキニルであり、これらの各々は、1〜4個のR8で適宜置換され;
R6、R7、およびR8 は、各々独立してC1-C6 アルキル、C1-C6 ヘテロアルキル、ハロ、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、シアノ、ニトロ、アミド、C1-C6 アルキルアミド、C2-C12 ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6 アルキル、C3-C7 シクロアルキル、C6-C10 アリール、ヘテロシクロアルキル、またはヘテロアリールであり、ここで、該C1-C6 アルキル、C1-C6 ヘテロアルキル、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヒドロキシル、C1-C6 アルコキシ、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、アミド、C1-C6 アルキルアミド、C2-C12 ジアルキルアミド、-S-、-S(O)2-、-C(O)O-、-C(O)-、-C(O)O-C1-C6 アルキル、C3-C7 シクロアルキル、C6-C10 アリール、ヘテロシクロアルキル、またはヘテロアリールの各々は、1〜3個のR9で適宜置換され;
各R9は、独立してC1-C6 アルキル、C1-C6 ヘテロアルキル、C1-C6 ハロアルキル、C1-C6 ハロアルコキシ、ヘテロシクロアルキル、C6-C10 アリール、ヘテロアリール、C4-C10 シクロアルキルアルキル、ヘテロシクロアルキル-C1-C6 アルキル、C7-C16 アリールアルキル、ヘテロアリール-C1-C6 アルキル、ハロ、ヒドロキシル、C1-C6 アルコキシ、C6-C10 アリールオキシ、C7-C16 アリールアルコキシ、C2-C8 アルコキシアルコキシル、アミノ、C1-C6 アルキルアミノ、C2-C12 ジアルキルアミノ、C1-C6 アルキル-アミノ-C1-C6 アルキル、C1-C6 アルキル-アミノ-C2-C12 ジアルキル、-S-、-S-C1-C6 アルキル、-S(O)2-C1-C6 アルキル、スルホンアミジル、アミド、ウレア、スルホニルウレア、アシル、-C(O)-C6-C10 アリール、-NHC(O)-C6-C10 アリール、-C(O)NH-C6-C10 アリール、-C(O)OH、-C(O)O-C1-C6 アルキル、-C(O)-C1-C6 アルキルアシル、ニトロ、またはシアノであり;
各Raは、C1-C6 アルキル、C1-C6 ハロアルキル、またはハロであり;
nは、1または2であり;そして
mは、1、2、または3である]
で示される化合物、またはその医薬的に許容される塩。 - 環Aが、フェニルまたはチアゾリルである、請求項27記載の化合物、またはその医薬的に許容される塩。
- R3が、ヒドロキシプロピルである、請求項27記載の化合物。
- R3が、ヒドロキシプロピルである、請求項30記載の化合物、またはその医薬的に許容される塩。
- Raが、独立してクロロ、フルオロ、またはメチルである、請求項30記載の化合物、またはその医薬的に許容される塩。
- 請求項1から32のいずれか1つに記載の化合物、またはその医薬的に許容される塩を含む、組成物。
- 対象においてTRPC5介在障害を処置する方法であって、請求項23から33のいずれかに1つに記載の化合物または組成物を対象に投与しその結果対象を処置することを含む、該方法。
- TRPC5介在障害が、神経精神障害、神経変性障害、腎症、および発作性障害からなる群より選択される、請求項34記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361789724P | 2013-03-15 | 2013-03-15 | |
US61/789,724 | 2013-03-15 | ||
PCT/US2014/027920 WO2014143799A2 (en) | 2013-03-15 | 2014-03-14 | Substituted xanthines and methods of use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016513717A true JP2016513717A (ja) | 2016-05-16 |
JP2016513717A5 JP2016513717A5 (ja) | 2017-04-20 |
JP6360149B2 JP6360149B2 (ja) | 2018-07-18 |
Family
ID=50680155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016502662A Active JP6360149B2 (ja) | 2013-03-15 | 2014-03-14 | 置換キサンチンおよびその使用方法 |
Country Status (32)
Country | Link |
---|---|
US (6) | US9359359B2 (ja) |
EP (1) | EP2970303B3 (ja) |
JP (1) | JP6360149B2 (ja) |
KR (1) | KR102227629B1 (ja) |
CN (2) | CN105143229B (ja) |
AU (1) | AU2014228206C1 (ja) |
CA (1) | CA2899646C (ja) |
CL (1) | CL2015002738A1 (ja) |
CY (1) | CY1119042T1 (ja) |
DK (1) | DK2970303T6 (ja) |
EA (1) | EA028815B1 (ja) |
ES (1) | ES2636835T7 (ja) |
HK (1) | HK1217329A1 (ja) |
HR (1) | HRP20170840T4 (ja) |
HU (1) | HUE033528T4 (ja) |
IL (1) | IL240216B (ja) |
LT (1) | LT2970303T (ja) |
MX (1) | MX370372B (ja) |
MY (1) | MY189912A (ja) |
NZ (1) | NZ711718A (ja) |
PE (1) | PE20151779A1 (ja) |
PH (1) | PH12015502141B1 (ja) |
PL (1) | PL2970303T6 (ja) |
PT (1) | PT2970303T (ja) |
RS (1) | RS56066B2 (ja) |
SG (1) | SG11201506479TA (ja) |
SI (1) | SI2970303T1 (ja) |
TW (1) | TWI609867B (ja) |
UA (1) | UA117470C2 (ja) |
UY (1) | UY35488A (ja) |
WO (1) | WO2014143799A2 (ja) |
ZA (1) | ZA201505414B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020526591A (ja) * | 2017-07-11 | 2020-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換キサンチン誘導体 |
JP2022512373A (ja) * | 2018-12-12 | 2022-02-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キサンチン誘導体 |
JP2022512374A (ja) * | 2018-12-12 | 2022-02-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キサンタン誘導体 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
LT2970303T (lt) | 2013-03-15 | 2017-07-25 | Hydra Biosciences, Inc. | Pakeistieji ksantinai ir jų panaudojimo metodai |
WO2016023831A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
WO2016159747A1 (en) | 2015-03-27 | 2016-10-06 | Latvian Institute Of Organic Synthesis | Ethynylxanthines, preparation and use as calcium ion channel modulators |
WO2016159746A1 (en) | 2015-03-27 | 2016-10-06 | Latvian Institute Of Organic Synthesis | Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis |
GB2553684B (en) | 2015-03-27 | 2020-06-03 | Latvian Inst Organic Synthesis | Ethynylxanthines, preparation and use for cancer treatment |
DK3280417T3 (da) * | 2015-04-08 | 2020-11-02 | Lewis And Clark Pharmaceuticals Inc | Xanthin-substitueret alkynyl karbamater/omvendte karbamater som a2b antagonister |
CN107118586A (zh) * | 2016-02-24 | 2017-09-01 | 中国科学技术大学 | 含氮杂环基取代的烯类化合物的用途 |
GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
WO2018157800A1 (en) * | 2017-02-28 | 2018-09-07 | National Institute Of Biological Sciences, Beijing | Mlkl inhibitors |
US11666577B2 (en) * | 2017-02-28 | 2023-06-06 | National Institute Of Biological Sciences, Beijing | MLKL inhibitors |
WO2019173327A1 (en) | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
CN112979651B (zh) * | 2021-04-09 | 2022-02-01 | 南京纽邦生物科技有限公司 | 一种副黄嘌呤的制备方法 |
CN113354646B (zh) * | 2021-07-06 | 2022-11-15 | 南开大学 | 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用 |
CN115636831A (zh) * | 2022-10-27 | 2023-01-24 | 中国药科大学 | 稠合嘧啶二酮类化合物、其用途以及药物组合物 |
US20240208976A1 (en) | 2022-12-20 | 2024-06-27 | Boehringer Ingelheim International Gmbh | Process for the preparation of 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione |
CN118373832A (zh) * | 2023-01-20 | 2024-07-23 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
WO2024165540A1 (en) | 2023-02-06 | 2024-08-15 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione |
WO2024164818A1 (zh) * | 2023-02-08 | 2024-08-15 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999035148A1 (en) * | 1998-01-02 | 1999-07-15 | Cell Therapeutics, Inc. | Compounds for increased bioavailability |
JP2002541258A (ja) * | 1999-04-09 | 2002-12-03 | セル セラピューティクス インコーポレーテッド | インターリューキン−12シグナルを阻害するための治療用化合物及びその使用方法 |
WO2008011518A2 (en) * | 2006-07-19 | 2008-01-24 | Diakine Therapeutics, Inc. | Encapsulation system |
JP2009504592A (ja) * | 2005-08-10 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | 選択的hm74aアゴニストとしてのキサンチン誘導体 |
JP2009518333A (ja) * | 2005-12-07 | 2009-05-07 | ユセベ ファルマ ソシエテ アノニム | キサンチン誘導体、その調製方法及びその使用 |
JP2009521485A (ja) * | 2005-12-22 | 2009-06-04 | ハイドラ バイオサイエンシズ インコーポレイテッド | 疼痛を処置するためのtrpa1阻害剤 |
WO2011114184A1 (en) * | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
WO2013023102A1 (en) * | 2011-08-09 | 2013-02-14 | Hydra Biosciences, Inc. | Inhibiting transient receptor potential ion channel trpa1 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4304650A1 (de) * | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
JP4191269B2 (ja) | 1996-05-17 | 2008-12-03 | 興和株式会社 | 新規なアニリド化合物及びこれを含有する医薬 |
JPH10318487A (ja) | 1997-05-16 | 1998-12-04 | Mitsubishi Gas Chem Co Inc | 真空断熱材用ゲッタ |
US6187780B1 (en) * | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
CN1440288A (zh) * | 2000-07-04 | 2003-09-03 | 诺沃挪第克公司 | 作为酶dpp-iv的抑制剂的杂环化合物 |
IL156315A0 (en) | 2000-12-07 | 2004-01-04 | Cv Therapeutics Inc | Abca-1 elevating compounds |
ES2444772T3 (es) * | 2001-02-24 | 2014-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Derivados de xantina, su preparación y uso como medicamentos |
US6825349B2 (en) * | 2001-11-09 | 2004-11-30 | Cv Therapeutics Inc. | A2B adenosine receptor antagonists |
WO2004106337A1 (en) * | 2003-05-06 | 2004-12-09 | Cv Therapeutics, Inc. | Xanthine derivatives as a2b adenosine receptor antagonists |
JP2007511528A (ja) | 2003-11-13 | 2007-05-10 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 心肥大および心不全の処置としてのtrpチャネル阻害方法 |
US7393827B2 (en) | 2004-12-30 | 2008-07-01 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring β-cell mass and function |
US8143254B2 (en) | 2005-02-18 | 2012-03-27 | Cornell Research Foundation, Inc. | Methods for modulating ion channels |
ES2339481T3 (es) * | 2005-09-06 | 2010-05-20 | Glaxosmithkline Llc | Compuestos de bencimidazol tiofeno como moduladores de plk. |
CA2637674A1 (en) | 2006-01-19 | 2007-07-26 | Abbott Laboratories | 2-imino-benzimidazoles |
WO2007101213A2 (en) | 2006-02-28 | 2007-09-07 | Kalypsys, Inc. | Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors |
WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
US20120148604A1 (en) | 2009-08-20 | 2012-06-14 | Transposagen Biopharmaceuticals, Inc. | Trp inhibitors and uses thereof |
US9260430B2 (en) | 2010-06-08 | 2016-02-16 | Hydra Biosciences, Inc. | Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents |
JP2013023102A (ja) | 2011-07-22 | 2013-02-04 | Panasonic Corp | 列車情報提供システム |
CN103121970B (zh) | 2012-12-04 | 2015-04-29 | 中国科学院昆明植物研究所 | 苯并咪唑及其衍生物,其药物组合物及其在制备抗抑郁药物中的应用 |
LT2970303T (lt) | 2013-03-15 | 2017-07-25 | Hydra Biosciences, Inc. | Pakeistieji ksantinai ir jų panaudojimo metodai |
-
2014
- 2014-03-14 LT LTEP14722452.1T patent/LT2970303T/lt unknown
- 2014-03-14 RS RS20170566A patent/RS56066B2/sr unknown
- 2014-03-14 US US14/210,781 patent/US9359359B2/en active Active
- 2014-03-14 TW TW103109651A patent/TWI609867B/zh active
- 2014-03-14 AU AU2014228206A patent/AU2014228206C1/en active Active
- 2014-03-14 CA CA2899646A patent/CA2899646C/en active Active
- 2014-03-14 EA EA201591615A patent/EA028815B1/ru not_active IP Right Cessation
- 2014-03-14 MY MYPI2015702631A patent/MY189912A/en unknown
- 2014-03-14 SG SG11201506479TA patent/SG11201506479TA/en unknown
- 2014-03-14 PT PT147224521T patent/PT2970303T/pt unknown
- 2014-03-14 DK DK14722452.1T patent/DK2970303T6/en active
- 2014-03-14 CN CN201480023267.0A patent/CN105143229B/zh active Active
- 2014-03-14 PL PL14722452T patent/PL2970303T6/pl unknown
- 2014-03-14 CN CN201710063554.XA patent/CN107082782B/zh active Active
- 2014-03-14 EP EP14722452.1A patent/EP2970303B3/en active Active
- 2014-03-14 ES ES14722452.1T patent/ES2636835T7/es active Active
- 2014-03-14 NZ NZ711718A patent/NZ711718A/en unknown
- 2014-03-14 KR KR1020157029667A patent/KR102227629B1/ko active IP Right Grant
- 2014-03-14 UA UAA201507774A patent/UA117470C2/uk unknown
- 2014-03-14 PE PE2015001829A patent/PE20151779A1/es active IP Right Grant
- 2014-03-14 MX MX2015011617A patent/MX370372B/es active IP Right Grant
- 2014-03-14 SI SI201430241T patent/SI2970303T1/sl unknown
- 2014-03-14 HU HUE14722452A patent/HUE033528T4/en unknown
- 2014-03-14 JP JP2016502662A patent/JP6360149B2/ja active Active
- 2014-03-14 WO PCT/US2014/027920 patent/WO2014143799A2/en active Application Filing
- 2014-03-17 UY UY0001035488A patent/UY35488A/es active IP Right Grant
-
2015
- 2015-07-28 ZA ZA2015/05414A patent/ZA201505414B/en unknown
- 2015-07-29 IL IL240216A patent/IL240216B/en active IP Right Grant
- 2015-09-15 PH PH12015502141A patent/PH12015502141B1/en unknown
- 2015-09-15 CL CL2015002738A patent/CL2015002738A1/es unknown
-
2016
- 2016-04-25 US US15/137,327 patent/US20160237089A1/en not_active Abandoned
- 2016-05-10 HK HK16105298.0A patent/HK1217329A1/zh unknown
-
2017
- 2017-06-01 HR HRP20170840TT patent/HRP20170840T4/hr unknown
- 2017-06-14 US US15/622,838 patent/US9969736B2/en active Active
- 2017-06-20 CY CY20171100647T patent/CY1119042T1/el unknown
-
2018
- 2018-05-02 US US15/968,941 patent/US10399982B2/en active Active
-
2019
- 2019-04-29 US US16/397,697 patent/US11208409B2/en active Active
-
2021
- 2021-11-10 US US17/523,838 patent/US11958854B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999035148A1 (en) * | 1998-01-02 | 1999-07-15 | Cell Therapeutics, Inc. | Compounds for increased bioavailability |
JP2002541258A (ja) * | 1999-04-09 | 2002-12-03 | セル セラピューティクス インコーポレーテッド | インターリューキン−12シグナルを阻害するための治療用化合物及びその使用方法 |
JP2009504592A (ja) * | 2005-08-10 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | 選択的hm74aアゴニストとしてのキサンチン誘導体 |
JP2009518333A (ja) * | 2005-12-07 | 2009-05-07 | ユセベ ファルマ ソシエテ アノニム | キサンチン誘導体、その調製方法及びその使用 |
JP2009521485A (ja) * | 2005-12-22 | 2009-06-04 | ハイドラ バイオサイエンシズ インコーポレイテッド | 疼痛を処置するためのtrpa1阻害剤 |
WO2008011518A2 (en) * | 2006-07-19 | 2008-01-24 | Diakine Therapeutics, Inc. | Encapsulation system |
WO2011114184A1 (en) * | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
WO2013023102A1 (en) * | 2011-08-09 | 2013-02-14 | Hydra Biosciences, Inc. | Inhibiting transient receptor potential ion channel trpa1 |
Non-Patent Citations (2)
Title |
---|
KIM M. J. ET AL.: "Molecular determinant of sensing extracellular pH in classical transient receptor potential channel", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 365(2), JPN6018000620, 2008, pages 239 - 245, ISSN: 0003719771 * |
YOSHIDA, J. ET AL.: "Capacitative Ca2+ entries and mRNA expression for TRPC1 and TRPC5 channels in human epidermoid carci", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 510(3), JPN6018000619, 2005, pages 217 - 222, ISSN: 0003719770 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020526591A (ja) * | 2017-07-11 | 2020-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換キサンチン誘導体 |
JP7114702B2 (ja) | 2017-07-11 | 2022-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換キサンチン誘導体 |
JP2022512373A (ja) * | 2018-12-12 | 2022-02-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キサンチン誘導体 |
JP2022512374A (ja) * | 2018-12-12 | 2022-02-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キサンタン誘導体 |
JP7408662B2 (ja) | 2018-12-12 | 2024-01-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キサンタン誘導体 |
JP7502299B2 (ja) | 2018-12-12 | 2024-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キサンチン誘導体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6360149B2 (ja) | 置換キサンチンおよびその使用方法 | |
EP2970316B1 (en) | Substituted xanthines and methods of use thereof | |
JP6667093B2 (ja) | ピリド[2,3−d]ピリミジン−2,4(1H,3H)−ジオン誘導体 | |
JP6573968B2 (ja) | TRPC5調節因子としての、精神神経障害の処置のためのチエノおよびフロ[2,3−d]ピリミジン−2,4[1H,3H]−ジオン誘導体 | |
EP3180342B1 (en) | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives | |
JP6695323B2 (ja) | ピリド[3,4−d]ピリミジン−2,4(1H,3H)−ジオン誘導体 | |
BR112015021164B1 (pt) | Composto de xantina substituída e seu sal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170314 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180413 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180605 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180621 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6360149 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |